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ABSTRACT
Black bear parathyroid hormone (PTH) and functional frag
ments thereof are provided. Also provided are methods of
using black bear PTH and functional fragments for increasing
cAMP in a bone-forming cell; reducing apoptosis in a bone
forming cell; decreasing the ratio of expression levels of Bax
protein to Bcl-2 protein in a bone-forming cell; increasing the
expression level of one or more of a bone matrix protein, a
transcriptional activator, or a transcriptional regulator in a
bone-forming cell; enhancing bone mineral density, increas
ing bone mass, decreasing bone loss, or reducing the inci
dence of bone fractures, or any combination thereof, in a
subject; also provided are antibodies directed against black
bear parathyroid hormone (PTH) and functional fragments
thereof.
10 Claims, 29 Drawing Sheets
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BLACK BEAR PARATHYROID HORMONE
AND METHODS OF USING BLACK BEAR
PARATHYROID HORMONE
STATEMENT REGARDING
FEDERALLY-SPONSORED RESEARCH
This invention was made with United States government
support awarded by the National Institutes of Health (NIAMS
AR050420, NIDDK DK078407 and AA143990) and the
National Science Foundation (IBN-0343515). The United
States government has certain rights in this invention.
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims priority and is a national stage
filing under 35 U.S.C. 371 of International Application No.
PCT/US2009/066974, filed Dec. 7, 2009. This application is
incorporated herein by reference in it’s entirety.
BACKGROUND
Bone loss diseases are currently a health threat for approxi
mately 44 million Americans, including 10 million with
osteoporosis and 34 million with low bone mass and at risk
for developing osteoporosis. The number of Americans with
osteoporosis is expected to rise by 2020. Consequently, a
large number of individuals are at risk for bone fracture due to
low bone mass. Approximately 40% of white women and
13% of white men over age 50 are at risk for hip, spine, or
forearm fracture within their lifetime. The costs associated
with osteoporosis-related fractures were approximately $18
billion dollars in 2002, and are expected to continue climbing.
In addition to primary (age-related) osteoporosis, disuse
osteoporosis is an important clinical problem, especially for
patients chronically immobilized due to stroke or spinal cord
injury. Fracture rates double compared to healthy controls in
the first year following spinal cord injury and are also elevated
compared to healthy controls after the onset of stroke. Disuse
increases fracture rates primarily because reduced skeletal
loading causes unbalanced bone remodeling which leads to
bone loss.
SUMMARY
In certain embodiments, the invention provides an isolated
polypeptide comprising at least 10 consecutive amino acid
residues of SEQ ID NO: 2 wherein the polypeptide comprises
at least one of amino acid residues 41 and 52 of SEQ ID NO:
2. In certain embodiments, isolated polypeptides comprising
amino acid residues 1-84 of SEQ ID NO: 2 are provided.
Polynucleotides encoding such polypeptides are also pro
vided. The present invention also provides an isolated poly
nucleotide comprising SEQ ID NO: 1.
In certain embodiments, the invention provides a method
of increasing cAMP levels in a bone-forming cell comprising
contacting the bone-forming cell with an effective amount of
at least one polypeptide selected from a polypeptide compris
ing amino acid residues 1-34 of SEQ ID NO: 2, a polypeptide
comprising amino acid residues 1-36 of SEQ ID NO: 2, a
polypeptide comprising amino acid residues 1-84 of SEQ ID
NO: 2, wherein contacting the bone-forming cell with the
polypeptide increases cAMP levels in the bone-forming cell.
In certain embodiments, the invention provides a method
of reducing apoptosis in a bone-forming cell comprising con
tacting the bone-forming cell with an effective amount of at
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least one polypeptide selected from a polypeptide comprising
amino acid residues 1-34 of SEQ ID NO: 2, a polypeptide
comprising amino acid residues 1-36 of SEQ ID NO: 2, a
polypeptide comprising amino acid residues 1-84 of SEQ ID
NO: 2, wherein contacting the bone-forming cell with the
polypeptide reduces apoptosis in the bone-forming cell.
In certain embodiments, the invention provides a method
of decreasing the ratio of expression levels of Bax protein to
Bcl-2 protein in a bone-forming cell comprising contacting
the bone-forming cell with an effective amount of at least one
polypeptide selected from a polypeptide comprising amino
acid residues 1-34 of SEQ ID NO: 2, a polypeptide compris
ing amino acid residues 1-36 of SEQ ID NO: 2, a polypeptide
comprising amino acid residues 1-84 of SEQ ID NO: 2,
wherein contacting the bone-forming cell with the polypep
tide decreases the ratio of expression levels of Bax protein to
Bcl-2 protein in the bone-forming cell.
In certain embodiments, the invention provides a method
of increasing the expression level of a bone matrix protein, a
transcriptional activator, or a transcriptional regulator in a
bone-forming cell comprising contacting the bone-forming
cell with an effective amount of at least one polypeptide
selected from a polypeptide comprising amino acid residues
1-34 of SEQ ID NO: 2, a polypeptide comprising amino acid
residues 1-36 of SEQ ID NO: 2, a polypeptide comprising
amino acid residues 1-84 of SEQ ID NO: 2, wherein contact
ing the bone-forming cell with the polypeptide increases the
expression level of the bone matrix protein, the transcrip
tional activator, or the transcriptional regulator in the bone
forming cell.
In certain embodiments, the invention provides a method
of enhancing bone mineral density, increasing bone mass,
decreasing bone loss, or reducing the incidence of bone frac
tures, or any combination thereof, in a subject, comprising
contacting a bone-forming cell in the subj ect with an effective
amount of at least one polypeptide selected from a polypep
tide comprising amino acid residues 1-34 of SEQ ID NO: 2,
a polypeptide comprising amino acid residues 1-36 of SEQ
ID NO: 2, a polypeptide comprising amino acid residues 1-84
of SEQ ID NO: 2, wherein contacting the bone-forming cell
with the polypeptide enhances bone mineral density,
increases bone mass, decreases bone loss, or reduces the
incidence of bone fractures in the subject.
In certain embodiments, the invention provides a method
of enhancing bone mineral density, increasing bone mass,
decreasing bone loss, or reducing the incidence of bone frac
tures, or any combination thereof, in a subject, comprising
contacting a bone-forming cell in the subj ect with an effective
amount of a polypeptide comprising bear parathyroid hor
mone or a functional fragment thereof, wherein contacting
the bone-forming cell with the polypeptide enhances bone
mineral density, increases bone mass, decreases bone loss, or
reduces the incidence of bone fractures in the subject.
In certain embodiments, the invention provides an isolated
polypeptide consisting of amino acid residues 1-34 of SEQ
ID NO: 2. In certain embodiments, the invention provides an
isolated polypeptide consisting of amino acid residues 1-36
of SEQ ID NO: 2. In certain embodiments, the invention
provides an isolated polypeptide consisting of amino acid
residues 1-84 of SEQ ID NO: 2.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows ultimate stress, a measure of bone strength,
and ash fraction, a measure of bone mineral content, which
both increase with age in black bears.
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FIG. 2 shows that serum osteocalcin levels are positively
correlated with serum parathyroid hormone (PTH) levels
(p=0.0007, n=27) in black bears for pooled pre-hibernation,
hibernation, and post-hibernation samples.
FIG. 3 shows normalized serum resorption (ICTP) and
formation (PICP and osteocalcin) marker concentrations dur
ing the 3 month disuse period.
FIG. 4 shows that the amount of PGE2 released by osteo
blastic cells was greatest when the cells were treated with
serum collected in the post-hibernation period.
FIG. 5 shows the sequence of the mature black bear PTH
protein compared to other known PTH sequences.
FIG. 6 shows that both human and black bear PTH 1-34
upregulate osteocalcin (n=2).
FIG. 7 shows the effects of human and black bear PTH 1-34
on apoptosis-related gene expression (n=4).
FIG. 8 shows uCT images of a proximal rat tibia (left), 1.6
mm analysis region of cortical and trabecular bone starting 2
mm distal to the proximal physis (top right), and the trabecu
lar analysis region (bottom right).
FIGS. 9A-9F show pCT images of bones from rats follow
ing sham ovariectomy (OVX) (FIG. 9A) or actual OVX fol
lowed by six (FIG. 9B) or fourteen (FIG. 9C) weeks of recov
ery with no PTH treatment, or by fourteen weeks of recovery
including eight weeks of treatment with 3 pg/kg (FIG. 9D), 10
pg/kg (FIG. 9E), or 30 pg/kg (FIG. 9F) black bear PTH1-34.
FIG. 10 shows a graph of bone volume as a fraction of total
volume (BV/TV) for bones from rats having had sham or
actual OVX procedures followed by treatment with vehicle
(saline) or human or bear PTH 1-34.
FIG. 11 shows a graph of bone mineral apparent density for
bones from rats having had sham or actual OVX procedures
followed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 12 shows a graph of trabecular strut number for bones
from rats having had sham or actual OVX procedures fol
lowed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 13 shows a graph of trabecular thickness for bones
from rats having had sham or actual OVX procedures fol
lowed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 14 shows a graph of trabecular bone mineralization
for bones from rats having had sham or actual OVX proce
dures followed by treatment with vehicle (saline) or human or
bear PTH 1-34.
FIG. 15 shows a graph of tibial cortical bone volume for
bones from rats having had sham or actual OVX procedures
followed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 16 shows a graph of tibial cortical porosity for bones
from rats having had sham or actual OVX procedures fol
lowed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 17 shows a graph of femoral cortical bone strength for
bones from rats having had sham or actual OVX procedures
followed by treatment with vehicle (saline) or human or bear
PTH1-34.
FIG. 18 shows a graph of serum calcium levels of rats
having had sham or actual OVX procedures followed by
treatment with vehicle (saline) or human or bear PTH1-34.
FIG. 19 shows the relative caspase-3 activity in MC3T3-S4
cells pretreated with 0-100 nM human or bear PTH peptides
and then subjected to serum starvation. LS means with stan
dard error bars are presented. Bars with different letters are
significantly (p<0.05) different from each other.
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FIG. 20 shows ultimate load of the femur in OVX rats
treated with vehicle (V), 2.5 nmol/kghPTHl-84, or 2.5 nmol/
kg bbPTHl-84.
FIG. 21 shows normalized ultimate load of the femur in
OVX rats treated with vehicle (V), 2.5 nmol/kghPTHl-84, or
2.5 nmol/kg bbPTHl-84.
FIG. 22 shows bone volume fraction in OVX rats treated
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg
bbPTHl-84.
FIG. 23 shows trabecular number in OVX rats treated with
vehicle (V), 2.5 nmol/kg hPTHl -84, or 2.5 nmol/kg bbPTHl84.
FIG. 24 shows trabecular thickness in OVX rats treated
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg
bbPTHl-84.
FIG. 25 shows trabecular separation in OVX rats treated
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg
bbPTHl-84.
FIG. 26 shows apparent mineral density in OVX rats
treated with vehicle (V), 2.5 nmol/kg hPTHl -84, or 2.5 nmol/
kg bbPTHl-84.
FIG. 27 shows material mineral density in OVX rats treated
with vehicle (V), 2.5 nmol/kg hPTHl-84, or 2.5 nmol/kg
bbPTHl-84.
FIG. 28 shows caspase 3/7 activity in cells cultured in
prehibernation, hibernation, and posthibernation bear serum.
FIG. 29 shows ultimate load of femurs in mice treated with
vehicle or various PTH peptides.
DETAILED DESCRIPTION
In humans and most other mammals, factors such as aging
and extended periods of disuse can lead to osteoporosis and
an increased risk of fracture. Disuse due to spinal cord lesion
significantly decreases bone mineral density, particularly in
the tibia and femur, and significantly reduces the cross-sec
tional moment of inertia of the femoral diaphysis. Thus, bone
bending strength is reduced by spinal cord injury and fracture
risk is increased. Disuse due to stroke also increases fracture
risk. In addition, mechanical unloading of bone can cause
rapid bone loss due to immediate increases in bone resorption
in addition to sustained decreases in bone formation. Disuseinduced changes in bone remodeling increase intracortical
porosity, and reduce the cross-sectional and mechanical prop
erties of long bone diaphyses. Unloading also considerably
reduces trabecular bone mass and microarchitecture.
The deleterious effects of disuse onbone may continue into
the remobilization period. Some bone may be recovered dur
ing remobilization, but recovery is slow and often incom
plete. For example, the rate of bone loss during bedrest is
more than three times greater than the rate of bone gain during
remobilization, and the recovery of bone lost in spaceflight
can be incomplete even after 5 years. When disuse-induced
changes in bone can be completely reversed by resumed
activity, the remobilization period is often 2 to 3 times longer
than the immobilization period. Bone formation decreases
and/or bone resorption increases in many situations that
reduce mechanical loads on bone. However, both resorption
and formation increase during canine forelimb immobiliza
tion, yet there is significant bone loss in that case. Likewise,
thigh bone turnover occurs in patients with spinal cord injury,
which leads to bone loss and increased fracture incidence.
In contrast to this, black bears do not suffer significant bone
loss due either to aging (FIG. 1) or, more importantly, to the
extended periods of disuse that occur during hibernation.
Hibernating black bears have immobilization and active peri
ods that can be approximately equal in length in northern
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regions. Data on serum markers of bone metabolism (see
below) suggest that both resorption and formation increase
during disuse in bears, with a normal lag time (i.e., reversal
period) between resorption and formation, and that the
increase in formation remains coupled and balanced with the
increase in resorption. Histological data from black bear iliac
crest biopsies also show increased resorption and formation
during inactivity. However, bears are unique in that trabecular
bone volume, bone mineral density, and bone mineral content
do not decrease during hibernation. Moreover, cortical bone
strength and ash fraction increase with age, and porosity
decreases with age in black bears, despite annual periods of
disuse. Cortical bone porosity is significantly lower in hiber
nating grizzly bears than in active grizzly bears, and femoral
cross-sectional geometry and strength are unaffected by
hibernation.
Bears have evolved many unique biological mechanisms to
survive long periods of immobilization without food. These
mechanisms appear to include the recycling of calcium and
other products of bone catabolism, since bears increase bone
turnover but do not excrete waste during hibernation. In
humans, bedrest-induced disuse osteoporosis is caused pri
marily by increased resorption without a corresponding
increase in formation. This results in hypercalcemia and a
negative calcium balance brought about by increased urinary
and fecal calcium. Since bears do not urinate or defecate
during hibernation, it is likely that most of the calcium
released from bone by resorption is recycled back into bone
via osteoblastic bone formation. Ionized calcium is found to
increase by about 23% during hibernation, possibly because
of the lag time between resorption and formation. Paradoxi
cally, black bear PTH levels are highest when levels of ion
ized calcium are highest (Example 2, Table 1). Taken
together, these findings suggest that bears have evolved bio
logical mechanisms to avoid osteoporosis.
The mechanisms that uncouple bone formation from
resorption during disuse in most animals are unknown, but
likely involve both mechanical and biochemical factors. Lack
of mechanical strain may lead to increased resorption by
initiating osteocyte apoptosis and concomitantly reducing
osteoblastic activity. Hormones such as human PTH can sen
sitize bone cells to mechanical stimulation and synergistically, with mechanical loading, increase bone formation.
Human PTH given once daily to humans increases bone mass
and decreases fracture incidence. Thus, in black bears, circu
lating PTH may sensitize bone cells to low levels of mechani
cal stimulation (possibly due to shivering or repositioning in
the hibernaculum) to help maintain bone formation during
disuse. PTH may also help maintain bone formation in black
bears by stimulating osteoblast differentiation and inhibiting
osteoblast apoptosis.
PTH is the primary regulator of blood calcium levels, and
thus plays a role in maintaining homeostatic serum calcium
levels in black bears during disuse. Serum PTH levels are
positively correlated with the bone formation marker osteo
calcin in active and hibernating black bears (FIG. 2), and both
osteocalcin and PTH increase during hibernation. In addition,
black bear PTH concentration is highest when ionized cal
cium concentration is highest. Since bone resorption
increases during hibernation but total serum calcium (tCa)
remains unchanged, increased levels of PTH likely cause
increased renal reabsorption of calcium, facilitating the recy
cling of mineral back into the bone with a balanced increase
in bone formation. This leads to the observed preservation of
trabecular and cortical bone properties like bone mineral
density (“BMD”) and cortical porosity. Bone resorption
increases during hibernation, but blood calcium concentra
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tion remains constant despite the fact that bears do not excrete
waste during hibernation. The calcium liberated by bone
resorption during hibernation may be recycled and put back
into bone by maintaining balanced coupling of bone forma
tion with bone resorption. This supports the idea that PTH has
anabolic effects in hibernating black bears and provides an
explanation for the bears’ distinctive ability to maintain bal
anced bone remodeling during hibernation. The anabolic
effects of PTH may be enhanced in black bears when physical
activity is resumed following arousal from hibernation.
Mechanical loading and human PTH have previously been
shown to act synergistically to increase bone formation in
vivo in rats and biochemical signaling in vitro. During remo
bilization in the spring, bone formation in the black bear, as
indicated by serum osteocalcin, remains higher than pre
hibernation levels.
The sequence for the polynucleotide that encodes black
bear (Ursus americanus) parathyroid hormone (PTH) (SEQ
ID NO: 1) was discovered as well as the polypeptide sequence
for the mature 84 amino acid PTH protein (SEQ ID NO: 2). In
addition, the cDNA (SEQ ID NO: 3) which encodes the full
length PTH protein (SEQ ID NO: 4), including a 25 amino
acid signal peptide (amino acid residues 1-25 of SEQ ID NO:
4) and a 6 amino acid propeptide (amino acid residues 26-31
of SEQ ID NO: 4) has been sequenced. The mature black bear
PTH protein differs from other known PTH proteins (FIG. 5).
Compared to human PTH, black bear PTH has 9 different
amino acid residues out of a total of the 84 amino acid resi
dues of the full-length, mature PTH polypeptide. Also
described herein are various methods of use for black bear
PTH and functional fragments thereof. It is specifically envi
sioned that polypeptide sub fragments comprising at least 10
consecutive amino acid residues of SEQ ID NO: 2 and includ
ing at least one of amino acid residues 41 or 52 can be used to
develop antibodies specific for black bear PTH. These anti
bodies can be used to quantify black bear PTH, e.g. in an
ELISA assay.
PTH receptors on the surface of bone-forming cells are
coupled to cyclic adenosine monophosphate (cAMP)-dependent second-messenger signaling pathways inside the cells.
These signaling pathways, in turn, lead to increased expres
sion of genes involved in bone formation such as those encod
ing type I collagen, osteonectin, and osteopontin. Since the
cAMP/protein kinase A pathway is responsible for the major
ity of PTH-induced increases in histological and serum indi
ces of bone formation, it follows that an increased cAMP
response can lead to greater bone formation. A relatively
small number of amino acid substitutions in the sequence of
a given PTH protein can stimulate greater cyclic adenosine
monophosphate (cAMP) production compared to the native
form. For example, ovariectomized rats demonstrated a 25%
greater bone formation response to daily 25 pg injections of
bovine PTH 1-34 than to rat PTH 1-34, where rat PTH 1-34
has 5 amino acid sequence differences compared to bovine
PTH 1-34. Injection of bovine PTH 1-34 results in a 37%
greater increase in bone volume fraction during treatment.
Thus, it is likely that the amino acid substitutions in black
bear PTH cause it to induce greater cAMP production in
bone-forming cells than human PTH. PTH, in general, elicits
a greater bone formation response by mechanisms such as
decreasing osteoblast apoptosis, increasing osteoblast differ
entiation via Runx2, downregulating SOST-based negative
feedback in osteocytes, and increasing production of mRNA
for bone matrix proteins, all via cAMP-mediated pathways.
Although it is not necessary to understand the mechanism of
an invention, it is believed that black bear PTH is likely more
osteogenic than other forms of PTH, which explains why
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black bears are uniquely able to maintain balanced bone
remodeling during disuse. In certain embodiments of the
present invention, contacting a bone-forming cell with black
bear PTH or a functional fragment thereof increases cAMP
levels in the bone-forming cell. In certain embodiments of the
present invention, the bone-forming cell is contacted with a
polypeptide comprising amino acid residues 1-34 or 1-36 of
SEQ ID NO: 2. In certain embodiments of the present inven
tion, the bone-forming cell is contacted with a polypeptide
comprising SEQ ID NO: 2.
As used herein, “contacting a cell” with a PTH polypeptide
includes adding the polypeptide to the culture solution, in the
case of in vitro experiments, or administering the polypeptide
to a subject using appropriate administration procedures for
polypeptide therapeutic agents. “Contacting a cell” also
includes introducing into a subject an exogenous polynucle
otide that encodes the desired polypeptide in an expression
system so as to synthesize and release the polypeptide in the
subject. As used herein, “bone-forming cells” includes, but is
not limited to, osteoblasts, osteocytes, bone lining cells,
chondroblasts, and chondrocytes. Suitably, the bone-forming
cell may be in a subject.
Bone-forming cells regularly turn over, with most of the
cells ’ death being due to programmed cell death, or apoptosis.
Given this regular rate of turnover, any mechanism that
decreases apoptosis of bone-forming cells will lead to an
increased number of bone-forming cells which presumably
will promote bone growth. Thus, in certain embodiments of
the present invention, contacting a bone-forming cell with
black bear PTH or a functional fragment thereof reduces
apoptosis in the bone-forming cell. In certain embodiments of
the present invention, the bone-forming cell is contacted with
a polypeptide comprising amino acid residues 1-34 or 1-36 of
SEQ ID NO: 2. In certain embodiments of the present inven
tion, the bone-forming cell is contacted with a polypeptide
comprising SEQ ID NO: 2.
Moreover, it is possible that several of the larger C-terminal
fragments of endogenous black bear PTH play a role in sea
sonal bone remodeling processes via binding to CPTHRs
(C-terminal PTH receptors). Specifically, C-terminal frag
ments of bear PTH may antagonize the calcemic effects of
PTH 1-84 and 1-34 by preventing osteoclastogenesis and
possibly by affecting mature osteoclast activity that would
normally occur in response to resorptive stimuli such as dis
use (Divieti, P. et al., 2002, Endocrinology 143(1): 171-6).
This may help bears to maintain homeostatic calcium levels
throughout hibernation. Thus, in certain embodiments of the
present invention, osteocytes and osteoblasts may be con
tacted with at least one polypeptide selected from a polypep
tide comprising amino acid residues 11-84 and a polypeptide
comprising amino acid residues 7-84 of SEQ ID NO: 2.
The protein Bax promotes apoptosis while the Bcl-2 pro
tein protects cells from apoptosis, and a decrease in the
expression ratio of Bax to Bcl-2 is indicative of a decrease in
apoptosis in the particular cell population. Thus, in certain
embodiments of the present invention, contacting a bone
forming cell with black bear PTH or a functional fragment
thereof decreases the ratio of expression levels of Bax protein
relative to expression levels of Bcl-2 protein in the bone
forming cell. In certain embodiments of the present invention,
the bone-forming cell is contacted with a polypeptide com
prising amino acid residues 1-34 or 1-36 of SEQ ID NO: 2. In
certain embodiments of the present invention, the bone-form
ing cell is contacted with a polypeptide comprising SEQ ID
NO: 2.
Example 11 shows that black bear PTH 1-34 decreases the
expression ratio of Bax/Bcl-2 in cultured cells whereas
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human PTH 1-34 increases the expression ratio of Bax/Bcl-2
(FIG. 7). Thus, black bear PTH 1-34 appears to be more
effective at preventing apoptosis than human PTH 1-34.
Without being bound by theory, this difference may be the
result of the two amino acid differences between human and
black bear PTH 1-34. These data suggest that bear PTH is
more anabolic than human PTH, since decreased osteoblast
apoptosis may contribute to the bone formation response
induced by PTH treatment.
Contacting a bone-forming cell with black bear PTH or a
functional fragment thereof also increases the expression
level of bone matrix protein, a transcriptional activator, or a
transcriptional regulator in the bone-forming cell. In certain
embodiments of the present invention, the transcriptional
activator is Runx2. In certain embodiments of the present
invention, the transcriptional regulator is c-fos. Exemplary
bone matrix proteins include, but are not limited to, osteocal
cin, osteopontin, and type I collagen. In certain embodiments
of the present invention, the bone-forming cell is contacted
with a polypeptide comprising amino acid residues 1-34 or
1-36 of SEQ ID NO: 2. In certain embodiments of the present
invention, the bone-forming cell is contacted with a polypep
tide comprising SEQ ID NO: 2.
Exogenous human PTH is used to treat post-menopausal
and age-related osteoporosis in humans, but it is not an ideal
therapeutic. Only recombinant human PTH 1-34 (LY333334,
Eli Lilly, Indianapolis Ind.) is currently approved for clinical
use, and only one form of recombinant human PTH 1-84 is
under consideration for approval by the U.S. Food and Drug
Administration (ALX1-11, NPS Pharmaceuticals, Parsippany, N.J.). Though LY333334 and ALX1-11 can stimulate
approximately the same magnitude of bone formation in vivo,
their biological actions are not identical. For example, PTH
1-34 down-regulates production of procollagen-1 mRNA,
whereas PTH 1-84 does not (Nasu et al., 1998, Endocr J, 45,
229-34). In addition, it has also been determined that the
C-terminal portion of human PTH, when cleaved from the
mature hormone, has important biological functions such as
inhibition of bone resorption.
Long-term usage of either LY333334 or ALX1-11 gener
ates osteosarcoma in rats, but preliminary results indicate that
human PTH 1-84 has a lower rate of carcinogenicity than
human PTH 1-34, possibly because C-terminal fragments of
exogenous human PTH 1-84 (arising from peripheral pro
teolytic processing) can bind to C-terminal PTH receptors
(CPTHRs) and increase osteocyte apoptosis. Thus, though
equally anabolic, human PTH 1-84 may be a superior
osteoporosis therapy compared to human PTH 1-34. How
ever, human PTH 1-84 cannot completely restore lost bone; it
has been suggested that men and women can lose between
20-30% of cortical and cancellous bone due to age-related
osteoporosis, but only 8% is recovered using ALX1-11 dur
ing its suggested treatment regimen. Therefore, there exists a
clinical need for osteoporosis treatments with greater osteo
genic capabilities.
In certain embodiments, the present invention is a method
of treating osteroporosis comprising administering an effec
tive amount of black bear PTH or a functional fragment
thereof to a subject in need thereof. In various embodiments,
the osteoporosis is primary or age-related osteoporosis and/or
disuse osteoporosis. In certain embodiments of the present
invention, contacting a bone-forming cell in a subject with
black bear PTH or a functional fragment thereof increases
bone mineral density, increases bone mass, decreases bone
loss orreduces the incidence of bone fracture in the subject. In
certain embodiments of the present invention, the bone-form
ing cell is contacted with a polypeptide comprising amino
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acid residues 1-34 or 1-36 of SEQ ID NO: 2. In certain certain embodiment, different functional fragments of black
embodiments of the present invention, the bone-forming cell bear PTH may be administered in combination with each
is contacted with a polypeptide comprising SEQ ID NO: 2.
other. The different functional fragments may be adminis
Suitably, contacting a bone-forming cell in a subject with tered concurrently or in any order that is suitable.
black bear PTH or a functional fragment thereof increases 5 The calcium, vitamin D, anabolic active agent, and/or anti
bone mineral density, increases bone mass, decreases bone resporptive active agent may be administered concurrently
loss or reduces the incidence of bone fracture by at least about with black bear PTH or functional fragments thereof or may
5% or at least about 10%. The increase in bone mineral be administered before or after black bear PTH or functional
density, increase in bone mass, decrease in bone loss or reduc fragments thereof. The calcium, vitamin D, anabolic active
tion in the incidence of bone fracture may be at least about 10 agent, and/or antiresporptive active agent may be in a separate
15%, at least about 30%, at least about 50%, at least about composition or may be in the same pharmaceutical compo
75% or at least about 90%. The increase in bone mineral sition as the black bear PTH or functional fragments thereof.
density, increase in bone mass, decrease in bone loss or reduc
Administration of black bear PTH or functional fragments
tion in the incidence of bone fracture is determined by mea thereof or compositions comprising black bear PTH or func
suring the desired characteristic on the same patient before 15 tional fragments thereof can be accomplished by any suitable
and after treatment by a technique known to one of ordinary technique. Black bear PTH or functional fragment thereof
skill in the art. For example, bone mineral density can be may be administered by any suitable route including, for
determined by methods involving taking dual energy x-rays example, oral, nasal, rectal, and parenteral routes of admin
(DEXA) orCT scans of bones in the spinal column, wrist, arm istration. As used herein, the term parenteral includes but is
or leg.
20 not limited to subcutaneous, intradermal, intravenous, intra
The subject may suitably be a mammal, including without muscular, intraperitoneal, and intrathecal administration,
limitation human, horse, dog, cat, mouse, bear, bovine, pig, or such as by injection. As is discussed above, administration of
deer. In certain embodiments, the subject is a post-meno- a polypeptide includes administration of an exogenous poly
pausal human female. The subject may have osteoporosis or nucleotide operably connected to a promoter such that the
may be at risk to develop osteoporosis. Risk factors for devel 25 polynucleotide expresses the polypeptide in the subject.
oping osteoporosis include: personal history of fracture after Administration of the polypeptide also includes administra
age 50; current low bone mass; history of fracture in a first- tion of a viral vector comprising a polynucleotide encoding
degree relative; being female; being thin and/or having a the polypeptide. Suitably, the viral vector is an adenoviral
small frame; advanced age; a family history of osteoporosis; vector.
estrogen deficiency as a result of menopause, especially early 30 Black bear PTH or functional fragments thereof, or com
or surgically induced; abnormal absence of menstrual periods positions comprising black bear PTH or functional fragments
(amenorrhea); anorexia nervosa; low lifetime calcium intake; thereof, can be administered continuously or at discrete time
vitamin D deficiency; use of certain medications (corticoster intervals as can be readily determined by a person skilled in
oids, chemotherapy, anticonvulsants and others); presence of the art. An ordinarily skilled clinician can determine a suit
certain chronic medical conditions, such as those that 35 able amount of black bear PTH or a functional fragment
decrease calcium absorption in the gut such as Crohn’s dis thereof to be administered to a subject.
ease; low testosterone levels in men; an inactive lifestyle;
The effective dose for any particular subject will depend
current cigarette smoking; excessive use of alcohol; and upon a variety of factors, including the disorder being treated
being Caucasian or Asian; although African Americans and and the severity of the disorder; activity of the specific com
Hispanic Americans are at significant risk as well. Moreover, 40 pound employed; the specific composition employed; the
women can lose up to 20 percent of their bone mass in the five age, body weight, general health, sex and diet of the subject;
to seven years following menopause, making them more sus route of administration; the rate of excretion or inactivation of
ceptible to osteoporosis.
black bear PTH or functional fragments thereof employed;
Black bear PTH or functional fragments thereof are also the duration of the treatment; other pharmaceuticals used in
useful as a preventative (rather than a restorative), or prophy 45 combination or coincidental with black bear PTH or func
lactic, measure to combat disuse osteoporosis or to prevent tional fragments thereof and like factors well known in the
osteoporosis in a subject at risk for developing osteoporosis. medical arts. For example, it is well within the level of ordi
Since bears appear to be the only animals that maintain bal nary skill in the art to start doses at levels lower than those
anced bone remodeling during disuse, black bear PTH or required to achieve the desired effect and to gradually
functional fragments thereof are also useful to prevent bone 50 increase the dosage until the desired effect is achieved.
loss during reduced skeletal unloading that occurs, for
Suitably, the dosage of black bear PTH or functional frag
example, in astronauts during spaceflight and in spinal cord ments thereof in certain embodiments is in a range of 0.10
injury patients after injury.
pg/kg per day to 40 pg/kg per day. In certain embodiments,
Black bear PTH or functional fragments thereof may be the dosage is in a range of 5 pg/kg per day to 20 pg/kg per day.
administered in combination with calcium and/or vitamin D. 55 In certain embodiments, the dosage is 10 pg/kg per day. In
Suitably, “Vitamin D” refers to the entire Vitamin D class of certain embodiments, the dosage is in a range of 10 pg/day to
compounds. Black bear PTH or functional fragments thereof 400 pg/day per subject. In certain embodiments, the dosage is
may also be administered in combination with other anabolic in a range of 20 pg/day to 40 pg/day per subject. In certain
or antiresporptive active agents. Suitable anabolic active embodiments, the dosage is 30 pg/day per subject.
agents include various fragments of human PTH (e.g. 1-34 60 For combination administration, one of ordinary skill in the
and 1-84), fluoride, GH, insulin-like growth factor I, statins, art would be able to determine the proper dosage of both the
and PYK2 kinase inhibitors. Suitable antiresorptive active black bear PTH or functional fragment thereof and the addi
agents include, but are not limited to estrogens, selective tional active agent, such as calcium, vitamin D, anabolics or
estrogen receptor modulators, calictonin, and bisphospho- antiresporptives. As is discussed above, the effective dose for
nates. In certain embodiments, an anabolic functional frag 65 any particular subject depends on a variety of factors. In
ment of black bear PTH (e.g. black bear PTH 1-34) is admin certain embodiments, the dosage of antiresorptives is about 5
istered in combination with an antiresorptive active agent. In to about 100 mg per day, the dosage of calcium is from about
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500 to about 1500 mg per day, the dosage of vitamin D is from
about 500 to about 1500 mg per day, the dosage of anaoblics
is from about 0.1 mg to about 0.5 mg per day or about 10
pg/day to 400 pg/day.
In certain embodiments the subject is a human. Suitably,
the daily dosages in certain embodiments are given for one
week, in certain embodiments for one month, in certain
embodiments for three months, in certain embodiments for
six months, in certain embodiments for one year, in certain
embodiments for one and a half years, in certain embodi
ments for two years, and in certain embodiments for three
years.
If desired, the effective daily dose may be divided into
multiple doses for purposes of administration. Consequently,
single dose compositions may contain such amounts or sub
multiples thereof to make up the daily dose. If desired, a
suitable delivery device is loaded with the effective daily dose
for more than one day, for example, for seven days, fourteen
days, twenty-one days, twenty-eight days or the like, and the
delivery device is used to repeatedly administer the desired
daily single dose or daily multiple doses for the desired total
number of days.As noted, those of ordinary skill in the art will
readily optimize effective doses and co-administration regi
mens as determined by good medical practice and the clinical
condition of the individual subject.
Compositions containing black bear PTH or functional
fragments thereof useful in the methods of the present inven
tion can be formulated according to known methods for pre
paring pharmaceutically useful compositions. Formulations
are described in detail in a number of sources which are well
known and readily available to those skilled in the art. For
example, Remington’s Pharmaceutical Science, by E. W.
Martin, describes formulations which can be used in the
disclosed methods. In general, the compositions will be for
mulated such that an effective amount of the black bear PTH
or functional fragment thereof is combined with a suitable
carrier in order to facilitate effective administration of the
composition.
The compositions used in the present methods can also be
in a variety of forms. These include, for example, solid, semi
solid, and liquid dosage forms, such as tablets, pills, powders,
liquid solutions or suspension, suppositories, injectable and
infusible solutions, and sprays. The form will depend on the
intended mode of administration and therapeutic application.
The compositions also suitably include conventional pharma
ceutically acceptable excipients which are known to those
skilled in the art. Examples of excipients include water for
injection, ethanol, dimethyl sulfoxide, glycerol, alumina,
starch, glacial acetic acid, sodium acetate, mannitol, metacresol, hydrochloric acid and/or sodium hydroxide to adjust
the pH of a composition to a suitable value, and equivalent or
otherwise suitable carriers and diluents. To provide for the
administration of such dosages for the desired application,
pharmaceutical compositions will comprise between about
0.1% and 99%, and suitably between about 1 and 15% by
weight of the total of one or more of the polypeptides of the
present invention based on the weight of the total composition
including the carrier or diluent.
As used herein, an “isolated” nucleic acid molecule, poly
nucleotide, polypeptide, or the like, as the case may be, refers
to a component that is at least partially purified from contami
nants (e.g., other species of polynucleotides, polypeptides, or
the like) that is found other than in its natural state. An isolated
nucleic acid, polynucleotide, or polypeptide may contain less
than about 50%, suitably less than about 75%, and most
suitably less than about 90%, of the cellular components with
which it was originally associated. A polynucleotide ampli
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fied using PCR so that it is sufficiently and easily distinguish
able (on a gel, for example) from the rest of the cellular
components is considered “isolated”. The nucleic acid mol
ecules, polynucleotides, and polypeptides of the invention
may be “substantially pure,” i.e., having the highest degree of
purity that can be achieved using purification techniques
known in the art.
As used herein, a “functional fragment” refers to any
region or portion of a polypeptide or polynucleotide which is
a region or portion of a laiger polypeptide or polynucleotide,
the region or portion having an activity or function attribut
able to the larger polypeptide or polynucleotide. For example,
a functional fragment of human PTH is the 1-34 region of
human PTH. Functional fragments of black bear PTH
include, but are not limited to, 1-34 and 1-36.
As used in this specification and the appended claims, the
singular forms “a,” “an,” and “the” include plural referents
unless the content clearly dictates otherwise. It should also be
noted that the term “or” is generally employed in its sense
including “and/or” unless the content clearly dictates other
wise. All publications, patents and patent applications are
herein expressly incorporated by reference in their entirety
for all purposes to the same extent as if each individual
publication or patent application was specifically and indi
vidually incorporated by reference. In case of conflict
between the present disclosure and the incorporated patents,
publications and references, the present disclosure should
control.
It also is specifically understood that any numerical range
recited herein includes all values from the lower value to the
upper value, i.e., all possible combinations of numerical val
ues between the lowest value and the highest value enumer
ated are to be considered to be expressly stated in this appli
cation. For example, if a concentration range is stated as 1%
to 50%, it is intended that values such as 2% to 40%, 10% to
30%, or 1% to 3%, etc., are expressly enumerated in this
specification. If a concentration range is “at least 5%,” it is
intended that all percentage values up to and including 100%
are also expressly enumerated. These are only examples of
what is specifically intended.
The following Examples are provided to assist in a further
understanding of the invention. The particular materials,
methods and conditions employed are intended to be illustra
tive of the invention and are not limiting upon the scope of the
invention.
Example 1
Sequencing of Black Bear PTH 1-84
Genomic DNA Extraction
Blood was collected from a captive female black bear and
stored at 4° C. Genomic DNA was extracted from the whole
blood samples within 2 weeks, using the GenomicPrep Blood
DNA Isolation Kit (Amersham Biosciences, Piscataway,
N.J.) according to the manufacturer’s instructions.
PCR Cloning and Sequencing
Black bear genomic DNA was used for PCR amplification
of PTH, using consensus primers designed based on align
ment of eight full-length mammalian PTH sequences avail
able in GenBank including bovine (Bos taurus, AAA30749),
cat (Felis catus, Q9GL67), dog (Cams familiaris, P52212),
human (Homo sapiens, NP_000306), macaque (Macacafascicularis, Q9XT35), mouse (Mus musculus, NP_065648),
pig (Sus scrofa, NP_999566), and rat (Rattus norvegicus,
NP_058740). PCR amplification was performed using 10-15
ng genomic DNA, 100 pM dNTPs, 0.2 pM each primer, and
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1 unit REDTaq (Sigma, St. Louis, Mo.) in 20 pL reaction
volume. PCR products were gel-purified using the UltraClean
GelSpin Kit (MoBio Carlsbad, Calif.) and cloned into the
pCRII vector using the TA cloning kit (Invitrogen, Carlsbad,
Calif.). DNA sequencing was performed using the DTCS
Quick Start kit and the CEQ8000 Genetic Analysis System
(Beckman Coulter, Fullerton, Calif.), following the manufac
turer’s instructions.
Sequence Analysis
Nucleotide sequences were searched against the GenBank
protein database using BlastX (Altschul et ah, 1997; Nucleic
Acids Res., 25,3389-402) to confirm their putative identity as
PTE1. Multiple sequence alignment was performed by ClustalW version 1.82 (Chenna et ah, 2003; Nucleic Acids Res.,
31, 3497-500). Phylogenetic analysis was carried out using
the neighbor-joining (NJ) method implemented in the
Molecular Evolutionary Genetics Analysis (MEGA) package
version3.0 (Kumaret al., 2004; BriefBioinform., 5,150-63),
with the pairwise deletion option for handling alignment
gaps, and with the Poisson correction model for distance
computation.
PTE1 Cloning and Sequence Analysis
Various primer combinations were used for PCR-based
cloning of PTE1 from black bear genomic DNA. Based on the
sequencing results of preliminary clones, a gene-specific
sense primer corresponding to the start codon was designed
and used along with a degenerate antisense primer containing
the stop codon to amplify the entire coding region of PTE1. A
second antisense primer covering the stop codon was
designed to generate a clone for sequence confirmation.
Sequence assembly revealed a precursor PTE1 protein of
115 amino acids, including a 25 amino acid signal peptide and
a 6 amino acid propeptide. The deduced mature protein is 84
amino acids, with a calculated molecular weight of 9,471
Daltons and a pi of 8.1. Black bear PTE1 shares 84-95%
sequence similarity with other mammalian PTEls, and is most
similar to dog PTE1 (91% identity, 95% similarity) (FIG. 5).
Interestingly, two amino acid residues, 41 and 52 of the
mature hormone, are unique to black bear PTF1.
Example 2
Levels of Bone Resorption and Formation Markers
During Ffibernation
Serum Samples
Blood samples were collected from five black bears (Ursus
americanus) held in a captive bear research facility. The Vir
ginia Polytechnic Institute and State University Animal Care
Committee approved all bear handling protocols (#98-069F&WS). The bears were anesthetized with a 2:1 mixture of
ketamine (100 mg/ml): xylazine (100 mg/ml); the dosage was
1 cc of the mixture per 45.5 kg of body weight. Body tem
peratures were 4° to 6° C. cooler during winter collection,
confirming that the bears were in a state of hibernation. No
urine or scat was present in the hibernation dens. Stressful
behavior was not observed during any of the handling proce
dures. Blood samples were drawn from the femoral vein
while the bears were anesthetized, and the samples were
transported to the laboratory in an ice-packed cooler. Imme
diately on return to the laboratory, the blood was centrifuged
to isolate the serum, which was frozen at -20° F. Blood
samples were collected from each bear every 10 days from the
first of October through the end of May. Ffibernation began in
early January and ended in early April. Thus, the collection
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dates encompassed an active pre-hibernation period, a disuse
hibernation period, and an active post-hibernation remobili
zation period.
Black Bear Osteocalcin Purification and RIA Procedures
Black bear cortical bone was broken into small fragments,
defatted with a mixture of 3 parts hexane and 2 parts isopro
panol, and lyophilized. The dried bone was ground to a fine
powder under liquid nitrogen, and the osteocalcin was solu
bilized as described by Flauschka et al. (1989, Physiol. Rev.,
69, 990-1047). Osteocalcin was purified from the resulting
EDTA extract by a modification of the method of Colombo et
al. (1993, J. Bone Miner. Res., 8, 733-43). Briefly, the crude
EDTA solution was diluted 2-fold and passed over a bulk
column containing 10 g Sepralyte C l8 particles (Analytichem International, Flarbor City, Calif.) previously activated
with methanol and equilibrated with 0.1% trifluoroacetic acid
in water (0.1% TFA). An extensive wash with 0.1% TFA was
followed by 30% methanol/0.1% TFA until UV absorbance
dropped to baseline. Osteocalcin was eluted with 80% methanol/0.1% TFA. Methanol was evaporated under a stream of
air and the remaining solution lyophilized. The resulting
dried protein was suspended in 0.05 MTris buffer, pFl 8.0 and
applied to a 5 ml Biorad Econo-Q column previously equili
brated with the same buffer. The column was developed with
a gradient from 0.1 to 0.6 M NaCl in 0.5 M Tris, pFl 8.0.
Osteocalcin eluted in a symmetric peak, the last to elute from
the column. Identity of this peak as osteocalcin was qualita
tively verified by reacting fraction aliquots with diazoben
zene sulfonic acid yielding a pink color in those fractions
containing osteocalcin, with intensity corresponding to peak
height. Both the Cl 8 and the Econo-Q column were new and
never exposed to protein from other species. Previous expe
rience with other species suggests the final osteocalcin peak is
greater than 99% pure. Concentration of black bear osteocal
cin in the final elute was determined with BCA reagents from
Pierce Chemical (Rockford, 111.).
Biochemical Assays
The serum was assayed for PTF1, 25-OF1 D, leptin, IGF-I,
and osteocalcin (a bone formation marker) using RIA and
ELISA.
Flighly purified black bear osteocalcin and black bear
serum were assayed by radioimmunoassay. The antibody was
guinea-pig anti-rat osteocalcin and tracer was 1251-labeled
rat osteocalcin. Dose dilutions of both rat osteocalcin stan
dard (Biomedical Technologies, Inc, Stoughton, Mass.) and
purified black bear osteocalcin were included in the assay.
Aliquots of 10 pi black bear serum per assay tube were
assayed in duplicate, and all samples were assayed at the
same time. Duplicates varied by less than 5%.
To observe changes in bone formation and resorption
markers during disuse, the mean values of osteocalcin for the
5 black bears were calculated for each time point during the
hibernation period. These values were normalized by the
maximum osteocalcin value during the hibernation period.
Similar calculations were done for measurements of PICP
(bone formation marker) and ICTP (bone resorption marker).
The normalized values of the resorption and formation mark
ers were plotted on the same graph to assess the temporal and
relative magnitude changes in bone resorption and formation
during disuse.
Using serum samples from hibernating bears obtained as
described above, ionized calcium concentration was mea
sured with an ion-selective electrode (Bayer Rapidlab 865,
Leverkusen, Germany).
Using serum samples obtained as described above, PTF1
was assayed with an ELISA kit from Immutopics Interna
tional (San Clemente, Calif.); the intra-assay coefficient of
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variation was 4.7%. 25-OH D was assayed with an ELISA kit
Example 3
from ALPCO Diagnostics (Windham, N.Ei.); the intra-assay
coefficient of variation was 5%. Leptinwas measured by RIA
PGE2 Release by MC-3T3 Osteoblasts is affected by
(Linco, St. Charles, Mo.); the intra-assay coefficient of varia
Seasonal Variations in Bear Serum
tion was 3.4%. IGF-I was measured by acid ethanol extrac- 5
tion RIA (Nichols Institute Diagnostics, San Juan Capistrano,
To assess the effects of seasonal variations in bear serum on
Calif.); the intra-assay coefficient of variation was 4.3%. osteoblast metabolism, MC-3T3 cells were treated with bear
Serum osteocalcin was measured by RIA as described above. serum and prostaglandin E2 (PGE2) release was quantified.
For all the serum metabolites, the mean values (for all bears MC-3T3 cells were grown in alpha minimum essential media
and all time points within a given season) were calculated for to (Invitrogen, Carlsbad, Calif.) supplemented with 10% fetal
each season (pre-hibernation, hibernation, and post hiberna bovine serum (Flyclone™, Logan, Utah) and 1% penicillintion) and compared by ANOVA. ANOVAs were followed up streptomycin solution at 37° C. in 5% C 02 for 24 hours. The
with Fisher’s PLSD tests for multiple mean comparisons. media was aspirated and replaced with 10 ml of fresh media
Natural log transformations were used to correct non-con containing 10% bear serum collected prior to hibernation,
stancy of variance for osteocalcin, PTF1, 25-OF1D, and IGF-I 15 during hibernation, or after hibernation. The cells were
to validate the ANOVAs. Linear regressions were used to allowed to grow for an additional 24 hours, and then the
assess the correlations between osteocalcin and the hor media was collected and frozen at -20° C. for PGE2 analysis.
mones. The volume of some serum samples was insufficient The cells were removed from the culture dishes using 0.25%
to run all assays; sample sizes for each assay are indicated trypsin in EDTA, pelleted by centrifugation, and quantified
with the results.
20 with a trypan blue and hemocytometer.
Results
The PGE2 levels were determined using the Biotrak™
The bone resorption marker (ICTP) began to increase PGE2 competitive enzyme immunoassay (Amersham Bio
immediately afterthe onset of hibernation (FIG. 3). Each data sciences, Piscataway, N.J.). The assay was performed in
point is the mean value from 5 bears. After 10-20 days, the duplicate using 50 pi samples from all experimental media
bone formation markers (osteocalcin and PICP) also 25 samples. The reaction was halted prior to endpoint determi
increased and appeared to remain coupled to the increased nation using 1M sulfuric acid and read at 450 nm using a
resorption for the duration of hibernation. This is consistent microplate reader (VERSAmax, Molecular Devices Corpo
with the 1-2 week histological “reversal” period between ration, Sunnyvale, Calif.). The duplicate optical density val
resorption and formation. These remodeling markers showed ues were corrected for nonspecific binding and were aver
trends of increased resorption and formation throughout the 30 aged, and compared to a standard curve to determine the
hibernation period, and formation appeared to remain amount of PGE2 in each well. These values were corrected for
coupled and balanced with resorption. Mean osteocalcin lev total media volume and normalized by the number of cells in
els were higher (p<0.0001) during and after hibernation com the sample. ANOVA was used to compare the normalized
pared to pre-hibernation (Table 1).
PGE2 between the three serum groups.
Flibernation ionized calcium levels were significantly 35 The amount of PGE2, released by osteoblastic cells treated
(p=0.0062) higher than the pre-hibernation levels (Table 1). with bear serum in vitro, was higher for treatment with post
During remobilization following arousal from hibernation, hibernation serum compared to pre-hibernation serum
ionized calcium levels did not significantly (p=0.37) increase (p=0.058) and hibernation serum (p=0.014) (FIG. 4). The
relative to hibernation levels, but they remained higher PGE2 release for cells treated with the hibernation serum was
(p=0.015) than pre-hibernation levels.
40 not significantly (p=0.48) different compared to the pre-hi
Osteocalcin was positively correlated with PTF1 (FIG. 2), bernation serum. The seasonal changes in PGE2 release
but not with25-OF!D, leptin, or IGF-I. PTF1 was significantly showed trends similar to the seasonal changes in serum IGF-I.
higher in the post-hibernation season than in the pre-hiberna P-values are for comparisons with the post-hibernation value.
tion (p=0.006) and hibernation (p=0.014) seasons. The Pre-hibernation and hibernation values were not different
increase in PTF1 during hibernation relative to pre-hiberna- 45 from each other (p=0.48).
tion was not significant (p=0.35). 25-OF1 vitamin D did not
show seasonal variations (p=0.64).
Example 4
Serum leptin did not change during hibernation relative to
pre-hibernation, but was significantly (p<0.004) lower during
Culture in Bear Serum Decreases the Ratio of Gene
post-hibernation remobilization (Table 1). IGF-1 signifi- 50
Expression of Bax to Bel-2 During Flibernation
cantly (p<0.0001) decreased during hibernation relative to
pre-hibernation and reached its highest value during remobi
Blood serum samples were removed from 4 female black
lization (Table 1).
bears between 2004-2005 as described above. Sample dates
TABLE 1
Mean Serum Metabolite Concentrations
16.9'’ (7.4)
0.709" (.150)
14.6'’ (4.5)
16.6 (16.3)
4.0'’ (0.7)
38"'“ (88)

[15]
[12]
[6]
[9]
[15]
[15]

Post-hibernation
[19]
P]
[9]
[9]
[19]
594c (207) [19]
oo

Osteocalcin (ng/ml)
Ionized calcium (mmol/L)
PTH (pg/ml)
25-OH D (nmol/ml)
Leptin (ng/ml)
IGF-I (ng/ml)

Hibernation
70.4* (43.1) [22]
0.871* (.093) [10]
25.3" (27.3) [14]
11.2 (6.2) [9]
3.8" (0.7) [22]
209* (52) [22]

.u
\Q
W
ON

Pre-hibernation

0.960* (.014)
41.4* (20.2)
16.0 (13.4)
3.1* (0.7)

Mean values are given in bold, standard deviations in parentheses, and sample sizes in brackets. For a given
metabolite, values with the same superscript are not significantly (p < 0.05) different. 25-OH D did not show
significant seasonal differences.
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encompassed a pre-hibemation active period, a hibernation
disuse period, and a post-hibernation remobilization period.
MC-3T3 osteoblastic cells were cultured for 24 hours in
media containing 10% bear serum, after which total RNA was
isolated using a BioRad AquaPure RNA Isolation Kit (#7326370, BioRad Laboratories, Hercules, Calif.). To generate
cDNA, reverse transcription was performed using Super
script II reverse transcriptase (Invitrogen, Carlsbad, Calif.),
and 0.5 pg Obgo(dT)12-18 primer at 42° C. for 20 minutes,
50° C. for 10 minutes and 42° C. for 1 hour in a gradient
thermocycler (Mastercycler gradient, Eppendorf, Westbury,
N.Y.). Primers for the pro-apoptotic protein Bax and the antiapoptotic protein Bcl-2 were designed using PrimerQuest
software (Integrated DNA Technologies, Coralville, Iowa)
and the NCBI gene bank sequences. Semi-quantitative PCR
was performed using RedTaq and a protocol consisting of 94°
C. for 2 minutes, cycles of 94° C. for 30 seconds, 69.5° C. for
30 sec and 72° C. for 1 minute, and a final extension at 72° C.
for 5 minutes. Band intensity was quantified using the ImageJ
software package (National Institutes of Health, Bethesda,
Md.) and normalized to the expression of three housekeeping
genes (Gapdh, (3-actin, cyclophillin).
ANOVA with Fisher’s Protected Least Significant Differ
ence (PLSD) post-hoc test was used to compare the ratio of
Bax to Bcl-2 for the three seasons (pre-hibemation, hiberna
tion, post-hibernation). Though it did not achieve statistical
significance (p=0.300), the Bax/Bcl-2 ratio decreased by
approximately 42% during hibernation relative to pre-hiber
nation. The lack of statistical significance was likely related to
the small sample size (n=2 for each season). These data sug
gest that semm from hibernating bears contains a biological
molecule that decreases osteoblast apoptosis. Since endog
enous PTH and the bone formation marker osteocalcin both
increase during hibernation (Donahue et al., 2006; J. Exp.
Biol., 209, 1630-8), it is possible that endogenous bear PTH
causes a decrease in osteoblast apoptosis during hibernation,
which in turn increases bone formation.
Example 5
Comparison of Effects of Black Bear vs. Human
PTH 1-84 or Sub fragments Thereof on cAMP in
Bone Cell Lines
Full-length recombinant black bear PTH (residues 1-84) is
produced and its effects on levels of cyclic adenosine mono
phosphate (cAMP) concentration in bone cell lines (MC-3T3
osteoblastic cells and MLO-Y4 osteocytic cells) are investi
gated and compared to results obtained using recombinant
human PTH 1-84. Equivalent experiments are conducted
using subfragments of black bear and human PTH, the subfragments including amino acid residues 1-34, 1-36, 7-84,
11 -84, and 41 -52 of the full-length (1 -84) mature protein. For
some experiments, black bear and human PTH polypeptides
are synthesized with solid-phase methods.
To determine the effect of various forms of recombinant
black bear and human PTH polypeptides on cAMP levels in
bone-forming cells, the cultured bone cells (MC-3T3 and
MLO-Y4) are contacted for 10 or 30 minutes with human or
black bear PTH full-length (i.e. amino acid residues 1-84)
polypeptide or one of the above-listed subfragments. After
the cell is contacted with the PTH polypeptide, cAMP con
centration in the cell is measured using a competitive binding
assay as described further below.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock
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concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) andMLOY4 cells (obtained from L.F. Bonewald, University of Mis
souri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3: 10% fetal bovine serum (FBS), MLO-Y4: 5% FBS
and 5% bovine calf serum), at 37° C. in 5% C 02. All proce
dures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTH Treatment on Intracellular cAMP Activity
MC-3T3 and MLO-Y4 cells are seeded at appropriate den
sities (MC-3T3: 50,000 cells/cm2, MLO-Y4 15,000 cells/
cm2) in 6-well plates. Cells are cultured overnight to reach
optimal confluence. The culture media is then aspirated and
replaced with media containing either 10% serum+vehicle (1
mM acetic acid) or 10% serum+100 nM PTH (human or bear
1-84, or a subfragment thereof). Cells are cultured under
these conditions for 10 or 30 minutes (Carter, P. H. et al.,
1999, J. Biol. Chem. 274(45), 31955-60; Chen, X. et al.,
2002, Am. J. Physiol. Cell Physiol. 283(5), C1432-40;
Schiller, P. C. et al., 1999, J. Bone Miner. Res. 14(9), 150412). Following culture, the cells are trypsinized, centrifuged,
and resuspended in lysis buffer. The suspension is incubated
for 10 minutes and centrifuged to separate cellular debris. The
supernatant from the cell lysate (following a 2-fold dilution)
is assayed for cAMP concentration using a competitive bind
ing assay (Cyclic AMP Assay #KGE002, R&D Systems,
Minneapolis, Minn.).
With each of the polypeptides tested, there is an increase in
cellular cAMP levels in response to the black bear PTH-based
polypeptide.
Example 6
Comparison of Effects of Black Bear vs. Human
PTH 1-84 or Sub fragments Thereof on Apoptosis in
Bone Cell Lines
Full-length recombinant black bear PTH (residues 1-84) is
produced and its effects on apoptosis in bone cell lines (MC3T3 osteoblastic cells and MLO-Y4 osteocytic cells) are
investigated and are compared to results obtained using
recombinant human PTH 1-84. Equivalent experiments are
conducted using sub fragments of black bear and human PTH,
the subfragments including amino acid residues 1-34, 1-36,
7-84, 11-84, and 41-52 of the full-length (1-84) mature pro
tein. For some experiments, black bear and human PTH
polypeptides are synthesized with solid-phase methods.
To determine the relative ability of black bear and human
PTH to prevent osteoblast and osteocyte apoptosis (under
pro-apoptotic conditions), cells are incubated with human or
black bear PTH 1-84, or one of the subfragments listed above,
for one hour. Afterwards, cells are treated for 6 hours with
dexamethasone to induce apoptosis. Apoptosis is quantified
with an ELISA, as described further below.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock
concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells
using either 0.1% or 10% FBS. Additional experiments with
less (0.1%) than the normal (10%) amount of FBS are run and
the results are analyzed to determine whether there is a sig
nificantly different response between experiments that are
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run with normal or lower levels of serum. In the experiments
reported in this Example, the results are not affected by the
amount of FBS that is used. Apoptosis protection studies
show that each of the polypeptides tested reduces or prevents
apoptosis in MC-3T3 cells.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) and MLOY4 cells (obtained from L. F. Bonewald, University of Mis
souri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3:10% fetal bovine serum (FBS), MLO-Y4: 5% FBS
and 5% bovine calf serum), at 37° C. in 5% C 02. All proce
dures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTF1 Treatment on Apoptosis
MC-3T3 cells are seeded at 50,000 cells/cm2, and MLOY4 cells are seeded at 15,000 cells/cm2 in 6-well plates and
cultured overnight to reach optimal confluence. The culture
media is aspirated and replaced with media containing either
10% serum+vehicle (1 mM acetic acid) or 10% serum+100
nM PTF1 (human or bear 1-84, or a subfragment thereof).
After a one-hour incubation (Jilkaet al., 1999; J. Clin. Invest.,
104,439-46), 10 pM dexamethasone or its vehicle (DMSO) is
added to each well and cells are incubated for 6 hours (Bellido, T. et al., 2003, J. Biol. Chem. 278(50), 50259-72; Jilka et
al., 1999, J. Clin. Invest., 104,439-46). The PTF1 polypeptide
or vehicle is left in situ during apoptosis induction because the
suppression of apoptosis by PTF1 is self-limiting (Bellido et
al., 2003). After 6 hours, cells are trypsinized, centrifuged,
resuspended, and counted using a hemocytometer. 50,000
cells are removed from the suspension and placed into lysis
buffer. The lysate supernatant (following centrifugation) is
removed for analysis and stored at -20° C.
Apoptosis is quantified from the lysate supernatant with an
ELISA (Cell Death Detection ELISA, #1544675, Roche
Applied Science, Indianapolis, Ind.). This assay detects
mono- and oligonucleosomes from fragmented cellular DNA
in the cytoplasmic fraction of cell lysates, and therefore pro
vides a good measure of the early and middle stages of apo
ptosis. Briefly, samples are diluted in buffer solution and
added to microplate wells coated with an anti-histone mouse
monoclonal (clone Ell 1-4) antibody. Lysate supernatant from
the vehicle-treated cells serves as a negative control. Optical
densities are measured at 405 nm following the addition of a
peroxidase-conjugated anti-DNA mouse monoclonal (clone
MCA-33) antibody, and the amount of apoptosis in each
sample is determined relative to its corresponding negative
control. All samples are assayed in duplicate.
Each of the polypeptides tested decreased apoptosis of the
cells (under pro-apoptotic conditions).
Example 7
Comparison of Effects of Black Bear vs. Fhiman
PTF1 1-84 or Sub fragments Thereof on Gene
Expression in Bone Cell Lines
Full-length recombinant black bear PTF1 (residues 1-84) is
produced and its effects on levels of gene expression in bone
cell lines (MC-3T3 osteoblastic cells and MLO-Y4 osteocytic cells) are investigated and are compared to results
obtained using recombinant human PTF1 1-84. Equivalent
experiments are conducted using sub fragments of black bear
and human PTF1, the subfragments including amino acid
residues 1-34, 1-36,7-84, 11-84, and 41-52 of the full-length
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(1 -84) mature protein. For some experiments, black bear and
human PTF1 polypeptides are synthesized with solid-phase
methods.
To determine the effect of black bear and human PTF1 on
regulation of bone matrix, transcriptional regulatory, anti
apoptosis (Bcl-2) genes, and the pro-apoptosis gene Bax,
cells are cultured for 1 or 3 hours with human or bear PTF1
1-84 or a subfragment. Gene expression is quantified with
real-time PCR.
For all of the experiments using recombinant polypeptides,
the lyophilized peptides are reconstituted to 100 uM stock
concentrations in 1 mM acetic acid, and diluted to 10 uM
working stock concentrations before use.
Additional experiments are performed with MC-3T3 cells
using either 0.1% or 10% FBS. Additional experiments with
less (0.1%) than the normal (10%) amount of FBS are run and
the results are analyzed to determine whether there is a sig
nificantly different response between experiments that are
run with normal or lower levels of serum. In the experiments
reported in this Example, the results are not affected by the
amount of FBS that is used. Real-time PCR is used to assess
gene expression levels at 1- and 3-hour time points following
addition of the polypeptide, showing in particular that black
bearPTFl l-34upregulates gene expression in MC-3T3 cells.
Cell Culture
MC-3T3 subclone 14 cells (ATCC, CRL-2594) andMLOY4 cells (obtained from L. F. Bonewald, University of Mis
souri, Kansas City, Mo.) are maintained in alpha-minimum
essential media, 1% penicillin/streptomycin, and 10% serum
(MC-3T3: 10% fetal bovine serum (FBS), MLO-Y4: 5% FBS
and 5% bovine calf serum), at 37° C. in 5% C 02. All proce
dures described herein are repeated with independent cell
cultures such that n=6 for all treatment combinations in each
assay.
Effects of PTF1 Treatment on Gene Expression
MC-3T3 cells are seeded at a density of 50,000 cells/cm2,
and MLO-Y4 cells are seeded at a density of 15,000 cells/cm2
in 6-well plates and cultured overnight to reach optimal con
fluence. The culture media are aspirated and replaced with
media containing either 10% serum+vehicle (1 mM acetic
acid) or 10% serum+100 nM PTF1 (human or bear 1-84, or a
sub fragment as listed above). Cells are cultured under these
conditions for 1 or 3 hours; these time points correspond with
PTFl-induced upregulation of c-fos and osteocalcin (Jiang et
al, 2004, J. Biol. Chem, 279, 5329-37; Chen et al, 2002).
Total RNA is isolated using the SV Total RNA Isolation
System (Promega, Madison, Wis.).
Reverse transcription to generate cDNA is performed
using Superscript II reverse transcriptase (Invitrogen, Carls
bad, Calif.), and 0.5 pg Ohgo(dT)12-18 primer at 42° C. for
20 minutes, 50° C. for 10 minutes and 42° C. for 1 hour in a
gradient thermocycler (Mastercycler gradient, Eppendorf,
Westbury, N.Y.). Primers for all genes of interest (osteocalcin,
osteopontin, type I collagen, c-fos, Runx2, Bax, Bcl-2,
SOST) and housekeeping genes (Gapdh, (3-actin, cyclophillin) are designed using PrimerQuest software (Integrated
DNA Technologies, Coralville, Iowa) and the NCBI gene
bank sequences, and the PCR conditions are optimized using
RNA from MC-3T3 and MLO-Y4 cells. Real-time PCR is
performed using the Mx3000P real-time PCR system (Stratagene, La Jolla, Calif.). The protocol involves a hot start at
95° C. for 10 minutes followed by 40 cycles of 95° C. for 30
seconds (denaturation), 69° C. for 1 minute (annealing) and
72° C. for 1 minute (extension). The exception to this protocol
is for c-fos, which has an annealing temperature of 66° C.
Each 25 pi reaction contains lx Absolute™ qPCR SYBR®
green mix (ABgene, Rochester, N.Y.), 0.1 pM forward and

21

US 8,987,201 B2

reverse primer, and 2.5 ng total RNA equivalent cDNA tem
plate. Gene expression is determined using the relative stan
dard curve method normalized to the geometric mean of the
three housekeeping genes. All samples are measured in dupli
cate, and any samples with a coefficient of variation (CV)
greater than 10% are reanalyzed.
The polypeptides cause an upregulation of bone matrix,
transcriptional regulatory, and transcriptional activator genes,
and a decrease in the expression ratio of Bax/Bcl-2.
Example 8
Comparison of the Effects of Black Bear Serum
from Different Seasons on Bone Cell Apoptosis and
Gene Expression, and Correlation with Serum Levels
of PTE1 and Osteocalcin
Blood samples are collected from at least 3 different female
black bears (Ursus americanus pallas) held in the Virginia
Tech Center for Bear Research between 2004 and 2005.
Serum from additional black bears is collected in subsequent
years. The Virginia Polytechnic Institute and State University
Animal Care Committee approved all bear handling proto
cols (#98-069-F&WS). The bears are anesthetized with a 2:1
mixture of ketamine (100-mg/ml):xylazine (100-mg/ml); the
dosage is 1 cc of the mixture per 45.5 kg of body mass. Blood
samples are drawn from the femoral vein while the bears are
anesthetized, and the samples are transported to the labora
tory in an ice-packed cooler. Immediately on return to the
laboratory, the blood is centrifuged to isolate the serum,
which is then frozen at -20° C. Blood samples are collected
from each bear every 10 days from the beginning of October
until the end of May. Elibernation begins in early January and
ends in early April. Thus, the collection dates encompass an
active pre-hibernation period, a disuse hibernation period,
and an active post-hibernation remobilization period.
Aliquots of 10 pi of bear serum are assayed in duplicate for
osteocalcin concentration by radioimmunoassay (PattersonAlien et al., 1982; Anal. Biochem., 120, 1-7). This assay has
previously been validated for bears (Donahue et al., 2006; J.
Exp. Biol., 209, 1630-8). The antibody is guinea-pig anti-rat
osteocalcin and tracer is 125I-labeled rat osteocalcin. Aliquots
of 100 pi of bear serum are assayed in duplicate for PTE1
concentration (Donahue et al., 2006; J. Exp. Biol., 209,16308) with an ELISA (Porcine Intact PTH ELISA Kit, #60-3305,
Immutopics, Inc., San Clemente, Calif.). This assay binds the
39-84 region of PTH, and requires the 13-34 region of PTH to
colorimetrically report PTH concentration. Thus, it provides
a good measure of intact (1-84) PTH concentration as well as
C-terminal subfragments 7-84 and 11-84. This ELISA has
been shown to cross-react with bear PTH (Donahue et al.,
2006; J. Exp. Biol., 209, 1630-8), and has 100% cross-reac
tivity with human PTH. To validate this assay for black bears,
samples of culture media containing 10 nM recombinant
black bear or human PTH 1-84 are assayed in duplicate. The
known concentration of the PTH samples is compared to the
measured concentration determined from the assay’s stan
dard curve. Any potential difference in cross-reactivity deter
mined from these samples is used as a correction for endog
enous black bear PTH concentration in the black bear serum
samples.
The procedures described above for recombinant black
bear PTH apoptosis and gene expression cell culture experi
ments with cultured bone-type cells are repeated, substituting
the 100 nM recombinant PTH-containing media with culture
media containing 10% black bear serum (from pre-hiberna
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tion, hibernation, or post-hibernation periods). The serum
volumes are calculated following the PTH ELISA described
above.
Serum from the hibernation and post-hibernation seasons
causes a greater prevention of apoptosis compared to pre
hibernation serum, because PTH is higher during hibernation
and post-hibernation than in pre-hibernation serum. Endog
enous serum PTH concentrations are inversely related to apo
ptosis levels, in that higher serum PTH levels correspond to
lower rates of apoptosis, i.e. serum PTH concentrations are
negatively correlated with apoptosis levels.
Example 9
In Vivo Testing of Bear PTH
Black bear PTH, either full-length (1 -84) or one of several
functional subfragments thereof (1-34; 1-36; 7-84; 11-84;
41-52), are tested in vivo for anabolic stimulation of bone
cells compared to an equivalent human PTH or subfragment.
Each of the PTH polypeptides is synthesized and suspended
in a pharmaceutically-appropriate carrier for subcutaneous
injection. Full-length PTH or a functional fragment thereof,
from either black bear or human, is administered to mice at a
dose of 40 pg/kg body weight daily for 7 weeks. Black bear
PTH or a functional fragment thereof cause greater increases
in bone strength, mass, and mineral content than the equiva
lent human PTH polypeptide.
Example 10
Use of Bear PTH as Prophylactic Agent to Reduce or
Prevent Bone Loss
Osteoporosis is induced in mice by hindlimb suspension (a
disuse model of osteoporosis) and by ovariectomy (a post
menopausal model of osteoporosis). After the hindlimb sus
pension begins or the ovariectomy is completed, the mouse is
given regular doses of black bear PTH or a functional frag
ment thereof. The mice treated with black bear PTH or func
tional fragments thereof show less bone loss than untreated
mice.
Example 11
Bear and human PTH 1-34 both upregulate gene
expression of osteocalcin, but only bear PTH 1-34
decreases the expression ratio of Bax/Bcl-2
MC-3T3 cells were incubated in vehicle or 100 nM syn
thetic bear or human PTH 1-34 for 3 or 6 hours (n=2 or 4).
Total RNA was isolated, and cDNA was generated with
reverse transcription. Primers for the bone matrix proteins
type I collagen and osteocalcin, the pro-apoptotic protein
Bax, the anti-apoptotic protein Bcl-2, and the housekeeping
genes Gapdh, (3-actin, and cyclophillin were designed using
PrimerQuest software (Integrated DNA Technologies, Coralville, Iowa). Real-time PCR was performed using the
Mx3000Preal-time PCR system (Stratagene, LaJolla, Calif.).
All samples were measured in duplicate. Gene expression
was determined using the relative standard curve method
normalized to the geometric mean of the three housekeeping
genes (Gapdh, (3-actin, and cyclophillin). Apoptosis-related
genes were analyzed as the expression ratio of Bax/Bcl-2,
since a decrease in this ratio is associated with decreased
apoptosis in vitro.
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Culture in human or bear PTH 1-34 for 6 hours did not
affect expression of type I collagen but substantially upregulated the expression of osteocalcin compared to the vehicle
control (FIG. 6). There were no significant differences
between human and bear PTH (p>0.09).
Culture in bear PTH 1-34 for 3 hours decreased the expres
sion ratio of Bax/Bcl-2, suggesting decreased apoptosis, but
culture in human PTH 1-34 for 3 hours increased the ratio,
suggesting increased apoptosis (FIG. 7). The difference
between bear and human PTH was statistically significant
(p=0.047).
Example 12
In Vivo Rat OVX Dose Response Study
Ninety female, 3-month old Sprague-Dawley rats were
obtained. Eighty (80) of the rats were ovariectomized (OVX)
and ten (10) underwent a sham OVX procedure (sham OVX)
in which the ovaries were left in the animal. The OVX animals
were randomly assigned into groups of ten for further experi
ments.
Following the actual or sham OVX procedure, all animals
were untreated for 6 weeks to allow bone loss. After the 6
week period of bone loss, groups of animals were injected for
a six- or eight-week period (daily for five days per week) with
vehicle (saline) or 3,10, or 30 pg/kg bear or human PTH 1-34.
The current dose of PTH1-34 for humans is approximately
0.3 pg/kg while a dose as low as 5 pg/kg has been shown to be
carcinogenic in rats (Tashjian et ah, J. Bone Mineral Res.
23(6): 803-811 (2008)). The sham OVX group as well as one
group of actual OVX rats were euthanized at six weeks while
the remaining animals were euthanized at fourteen weeks
following the OVX procedure. Samples were obtained from
the euthanized animals for further analysis.
Three-dimensional images of bones were obtained using
micro-computed tomography (pCT). The three-dimensional
images were then used to quantify bone parameters, as
explained below. The measurements were conducted on a 1.6
mm-thick region that begins at a position 2 mm from the
growth plate (FIG. 8). Bone samples were obtained and ana
lyzed from sham (FIG. 9A, “Sham OVX 6 weeks”) and actual
(FIG. 9B, “OVX 6 weeks”) OVX rats that were euthanized at
six weeks after the procedure, as well as a group of actual
OVX rats that were euthanized at fourteen weeks after the
procedure (FIG. 9C, “OVX 14 weeks”). The rats in the OVX
14 group were given injections of vehicle (saline) for 8 weeks
following the 6 week bone loss period, in parallel with the
PTH1-34 injections for eight weeks (FIGS. 9D, 9E, and 9F).
The samples shown in FIGS. 9D, 9E, and 9F were obtained
from rats that were injected for eight weeks following the 6
week bone loss period, with 3, 10, or 30 pg/kg black bear
PTH1-34 (“bbPTH”), respectively.
As can be seen in the images, bones from rats at 6 weeks
(FIG. 9B) and 14 weeks (FIG. 9C) following OVX surgery
demonstrated noticeable amounts of bone loss compared to
bones from sham OVX (FIG. 9A) and bbPTH-treated rats
(FIGS. 9D-9F). Rats treated with black bear PTH1-34 had
dose-dependent greater bone mass at each of the dosage lev
els (FIGS. 9D-9F) compared to the OVX rats that received
injections of vehicle (saline) only (FIG. 9C).
Differences in bone parameters between the sham OVX,
OVX, and PTH-treated rats were quantified. FIG. 10 shows
bone volume as a fraction of total volume (BV/TV) for the
various treatment groups. The baseline level of bone volume
fraction in the presence of ovaries (“sham baseline,” light
diamond) and the baseline level six weeks after loss of ovaries
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and in the absence of PTH treatment (“OVX baseline,” dark
diamond) are shown at the left, in the column labeled “6
weeks.” Treatment of OVX rats with vehicle (saline) alone for
fourteen weeks (“OVX vehicle,” triangle) led to a further
decline in bone volume fraction. Treatment of OVX rats with
human (“hPTHl-34,” squares) or black bear (“bbPTHl-34,”
circles) PTH1-34 increased bone volume fraction in a dosedependent manner. At the highest dose of 30 pg/kg, treatment
with human PTH led to a significantly (p<0.05) greater bone
volume fraction than treatment with bear PTH or with vehicle
(saline) alone. Treatment with human PTH produced a sig
nificantly (p<0.05) greater bone volume fraction than treat
ment with vehicle (saline) alone at all three levels tested,
while bear PTH produced a significantly (p<0.05) greater
bone volume fraction than treatment with vehicle (saline)
alone at 10 pg/kg and 30 pg/kg.
Similarly, bone mineral apparent density was determined
for each of the samples (FIG. 11) and is shown as milligrams
hydroxyapatite per cubic centimeter (“App.Dn
(mgHA/ccm)”). The bone mineral apparent density was sig
nificantly higher (p<0.05) for bones of OVX rats treated with
3,10, or 30 pg/kg hPTH or bbPTH than for bones of OVX rats
treated with vehicle (saline) alone. The bone mineral apparent
density for OVX rats treated with 30 pg/kg hPTH was sig
nificantly higher (p<0.05) than OVX rats treated with 30
pg/kg bbPTH.
The number and thickness of trabecular struts were also
determined for bones from sham OVX, OVX without PTH
treatment, and PTH-treated OVX rats (FIG. 12). The symbols
show the trabecular number per millimeter (“Tb.N
(mnT-1)”) for sham OVX rats (“sham baseline,” light dia
monds), OVX rats treated with vehicle (saline) alone and
euthanized at six weeks (“OVX baseline,” dark diamonds),
OVX rats treated with vehicle (saline) alone for eight weeks
and euthanized at fourteen weeks (“OVX baseline,” dark
diamonds), and OVX rats treated with 3, 10, or 30 pg/kg
human (“hPTHl-34,” squares) or bear (“bbPTHl-34,”
circles) PTH1-34 (FIG. 12).
The average thickness of the trabecular struts was also
determined (FIG. 13). Treatment with either bear or human
PTH significantly (p<0.05) increased the average thickness of
the trabecular struts (“Tb.Th (mm)”) compared to vehicletreated controls.
Black bear PTH1-34 showed a trend of greater trabecular
bone mineralization (“M.Dn (mgHA/ccm)”; FIG. 14) with
increasing dose compared to human PTH1-34. Treatment of
OVX rats with either bear (“bbPTHl-34,” circles) or human
(“hPTHl-34,” squares) PTH1-34 produced significantly
(p<0.05) greater trabecular bone mineralization than OVX
rats treated with vehicle (saline) alone.
Human PTH1-34 (“hPTH,” squares) is better than bear
PTH1-34 (“bPTH,” circles) at increasing tibial cortical bone
volume (“BV(mnT2),” FIG. 15). Overall, however, changes
in the bone cortical region were moderate relative to the
changes observed in bone trabeculae.
Tibial cortical porosity in bones of OVX rats was observed
to be significantly (p<0.05) decreased when the rats were
treated with middle (10 pg/kg) and higher doses (30 pg/kg) of
either bear (“bbPTFH-34,” circles) or human (“hPTHl-34,”
squares) PTH1-34 relative to bones from OVX rats treated
with vehicle (saline) alone (FIG. 16). However, only higher
doses (30 pg/kg) of human or bear PTH1-34 produced sig
nificant (p<0.05) increases in femoral cortical bone strength
relative to vehicle-treated controls (FIG. 17).
An additional benefit that black bear PTH1 -34 may confer
over human PTH1-34 is lower serum calcium. Hypercalce
mia (elevated serum calcium) is a side effect of PTH treat -
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ment in humans. In the present experiments, serum calcium
levels were seen to be lower in rats treated with bear PTH 1-34
compared to human PTH1-34, although the results are not
significant at the p<0.05 level. However, statistical analyses
predict that serum calcium concentrations would be signifi
cantly (p<0.05) lower in black bear PTH1-34 treated rats if
the sample size were doubled. Thus, black bear PTH1-34
treatment may reduce the incidence of this side effect.
The experiments show that black bear PTH1 -34 is equally
effective as human PTH1 -34 at producing dramatic increases
in trabecular bone formation. Human PTH1-34 was observed
to be more effective than bear PTH1-34 for several param
eters at the highest dose (30 pg/kg), although this is 100 times
higher than doses given to humans. However, at lower and
more clinically-relevant doses, bear PTH1-34 was as effec
tive as human PTH1-34 at increasing important parameters
related to reducing bone fracture likelihood.
Example 13
Bear PTH1-34 and Bear PTH1-84 Reduce Caspase-3
Activity in Cultured Mouse Osteoblasts
Cell Culture
MC3T3 subclone 4 cells (ATCC, CRL-2593) were main
tained in standard culture media (89% alpha-minimum essen
tial media, 1% penicillin/streptomycin, and 10% FBS) at 37°
C. in 5% C02. Cells were not used beyond passage 30.
PTH Attenuation of Serum-Starvation Induced Apoptosis
MC3T3 cells were seeded at a density o f20,000 cells/well
in 96-well plates and allowed to attach overnight. Culture
media was then aspirated and replaced with 100 pi of culture
media containing 10% FBS and either vehicle (PBS) or PTH
(10-100 nM) for one hour, after which media was aspirated
and cells were washed with PBS to remove residual serum. To
induce apoptosis, cells were incubated in control or serumfree media for 6 hours. Replacement media contained 89%
alpha-minimum essential media, 1% penicillin/streptomycin,
and either 10% FBS (control media) or 0% FBS (starvation
media). After starvation, media was aspirated, cells were
washed with PBS, and 50 pi of fresh PBS was added to each
well. Caspase-3/7 activity was determined by cleavage of a
DEVD substrate (Caspase-Glo 3/7 Assay, #G8093, Promega
Corporation). Measured luminescence values were fit to a
standard curve prepared with known concentrations of
recombinant human caspase-3 (#SE-169, BIOMOL
Research Laboratories Inc.). Five wells of each treatment
were run per 96-well plate, and procedures were repeated on
a minimum of 10 plates.
Statistics
Attenuation of caspase-3/7 activation was compared
between peptide, vehicle, and control-treated samples with
ANOVA with Fisher’s PLSD, blocking by experiment repli
cation. Caspase-3/7 activity values were normalized to the
control media (unstarved cells) caspase-3/7 level within each
replication, and analysis of covariance (ANCOVA) was used
to compare the dose response behavior of the peptides, treat
ing concentration as the covariate.
Serum starvation significantly (p<0.0001) increased
caspase-3/7 activity (an early indicator of apoptosis) in the
vehicle and PTH-pretreated samples compared to nonstarved cells in this experiment (FIG. 19). All PTH pretreat
ments significantly (p<0.0001) lowered caspase-3/7 activity
compared to vehicle-treated cells. PTH-induced reduction in
caspase-3/7 activity did not demonstrate a dose-dependent
behavior (p=0.890), therefore, all concentrations were pooled
within groups for between group comparisons. Of the four
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peptide groups, bbPTH 1-34 demonstrated the greatest
attenuation of serum starvation-induced apoptosis; mean
caspase-3/7 activity in the bbPTH 1-34 group were signifi
cantly lower than the hPTH 1-34 group (p=0.006) and either
PTH 1-84 group (p<0.018) (FIG. 19). In contrast, the differ
ence in caspase-3/7 activity between the bbPTH 1-84 and
hPTH 1-84 groups approached significance (p=0.090) with
hPTH 1-84 indicating lower levels of apoptosis (FIG. 19).
Example 14
In Vivo Effects of Bear PTH1-34 and Bear PTH1-84
in Male Swiss-Webster Mice
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Animals
All handling procedures and experiments were approved
by the Michigan Technological University Institutional Ani
mal Care and Use Committees. Male Swiss-Webster mice
were obtained from a commercial breeder (Harlan, India
napolis, Ind.). All animals were maintained on a 12-h light/
12-h dark cycle, and were permitted free access to water and
food containing 0.95% calcium (Purina Rodent Diet #5001).
In the first experiment, 11 wk old mice received daily (5
days/week) subcutaneous injections of 2.5 nmol/kg PTH
1-34 (hPTH 1-34 or bbPTH 1-34) or acidic saline vehicle
(0.15 MNaCl+0.001 NHC1) for 8 weeks (n=10mice/group).
In the second experiment, 12 wk old mice received daily (5
days/week) subcutaneous injections of 2.5 nmol/kg PTH
1-84 (hPTH 1-84 or bbPTH 1-84) or acidic saline vehicle for
8 weeks (n=10 mice/group). All PTH- and vehicle-treated
animals received subcutaneous injections of calcein at a dos
age of 10 mg/kg on days 12 and 3 before death to label
mineralizing bone surfaces. Twenty-four hours following the
last treatment injection, mice were sacrificed by carbon diox
ide asphyxiation. Right femurs were fixed in 10% neutral
buffered formalin. Left femurs were wrapped in 0.15M saline
soaked gauze and stored at -20 deg C. Left tibias were stored
in 70% ethanol at 4 deg C.
Trabecular Bone Structure and Mineralization in the Proxi
mal Tibia
Trabecular bone architecture and mineralization were
evaluated in the left proximal tibial metaphysis (0.7 mm distal
to the growth plate) using micro-computed tomography.
Tibias from experiment 1 were scanned on a pCT35 scanner
(Scanco Medical AG, Basserdorf, Switzerland) at 3.5 pm
(high) resolution. Tibias from experiment 2 were scanned on
a pCT40 scanner (Scanco Medical AG, Basserdorf, Switzer
land) at 7 pm (high) resolution. Bones were scanned in 70%
ethanol. Trabecular bone volume fraction (BV/TV, %), trabe
cular number (Tb.N, mm"1), trabecular thickness (Tb.Th, m),
trabecular separation (Tb.Sp, m), trabecular apparent mineral
density (App.Mn.Dn, mgHA/cm3) and trabecular tissue min
eral density (Mat.Mn.Dn, mgHA/cm3) were computed using
the manufacturer’s software.
Cortical Bone Mechanical Properties of the Femur
Left femurs were loaded to failure in 3 -point bending on an
Instron mechanical testing system (Model #8872, Canton,
Mass.) at a rate of 1 mm/min. Bones were oriented with the
anterior surface in compression. The lower testing fixture
supports were separated by a span of 10 mm, and all fixtures
had rounded contact points (radius=l mm) to prevent local
ized stress concentrations in the bone. Ultimate load was
calculated using the load-deformation data from testing.
Cortical Bone Mineral Content, Geometrical Properties, and
Dynamic Histomorphometry
Following the bending test, the left femoral diaphyses were
ashed in a furnace to determine mineral content (ash fraction).
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Right femoral diaphy ses were embedded in methyl methacry all six experimental groups (from both the PTH 1-34 and PTH
late and sectioned with a diamond saw to expose the midshaft 1-84 studies) were compared with ANOVA and Fisher’s
cross-section. Images of the midshaft cross-sections were PLSD. A significance of p<0.05 was used for all comparisons.
captured using a digital camera (Spot Insight QE, Diagnostic Results
Instruments Inc., Sterling Heights, Mich.), and Scion Image 5 Trabecular Bone Structure and Mineralization in the Proxi
analysis software (Scion Corporation, Frederick, Md.) was mal Tibia
used to calculate the periosteal area (Ps.Ar), cortical area
Trabecular bone microCT data are presented in Tables 2
(Ct.Ar), and endosteal area (Es.Ar) for each sample. Cortical and 3. There were no significant differences between experi
bone thickness (Ct.Th) was calculated in 0.1 mm increments mental groups in the PTH 1-34 study, although trabecular
for each anatomical quadrant and for the entire cross-section to bone material density tended to be lowest in mice treated with
using image analysis software (Bioquant Osteo, Nashville, bbPTH 1-34 (Table 2). In contrast, bone volume fraction was
Term.). Thin sections from the midshaft of the right femur greater in the proximal tibia of mice treated with bbPTH 1-84
were ground to a thickness of 50 pm and mounted on glass compared to hPTH 1-84 (Table 3). Differences between the
slides. Images of calcein labels were captured at lOOx mag effects of bbPTH 1-84 and hPTH 1-84 on bone volume frac
nification and periosteal and endosteal mineral apposition 15 tion were significant (p=0.013), with bbPTH being the more
rates (Ps.MAR and Es.MAR, respectively) and mineralizing efficacious therapy. The increase in bone volume fraction in
surfaces (Ps.MS/BS and Es.MS/MS) were quantified (Bio the bbPTH 1-84 treated mice was likely influenced by trabe
quant) for each femur.
cular thickness since trabecular thickness tended to be greater
in mice treated with bbPTH 1-84 compared to mice treated
In Vivo Experiments Statistics
All bone geometrical, architectural, and mineral properties 20 with hPTH 1-84 (p=0.089). Trabecular number and trabecu
were normalized by body mass to account for potential varia lar separation were not significantly different between groups
tion in animal size (31-33). Trabecular bone properties quan in the PTH 1-84 study (Table 3). Trabecular apparent mineral
tified by micro-computed tomography were compared by density was highest in mice treated with bbPTH 1-84 com
ANOVA between vehicle, bear, and human PTH-treated mice pared to other treatments; the difference in the effects of
within each study (PTH 1-34 or PTH 1-84). The microCT 25 bbPTH 1-84 and hPTH 1-84 was statistically significant
parameters were not directly compared between the PTH (p=0.019) (Table 3). Trabecular material mineral density
1-34 and PTH 1-84 studies because analyses were conducted tended to be highest in mice treated with bbPTH 1-84 (Table
on different microCT machines. For all other bone properties, 3).
TABLE 1
Trabecular bone architectural properties and mineral density
in the proximal tibia of mice from the PTH 1-34 study
Bone Property

Vehicle

BV/TV (%/kg)
Tb. N (l/mm*kg)
Tb. Th (mm/kg)
Tb. Sp (mm/kg)
App. Mn. Dn
(mgHA/(cm3*kg))
Mat. Mn. Dn.
(mgHA/(cm3*kg))

1.46
115.2
0.96
9.17
1829

(0.68)
(27.2)
(0.11)
(2.48)
(994)

32563 (2743)

hPTH 1-34

bbPTH 1-34

1.35
105.0
1.05
9.57
1783

1.34
107.4
1.02
8.76
1720

(0.76)
(26.8)
(0.10)
(2.29)
(1052)

31281 (1957)

ANOVA
p-value

(0.35)
(19.1)
(0.21)
(2.39)
(537)

0.883
0.629
0.446
0.752
0.963

30457 (1412)

0.099

Standard deviations are shown in parentheses.
See text for explanations of abbreviations.

TABLE 2
Trabecular bone architectural properties and mineral density
in the proximal tibia of mice from the PTH 1-84 study.
Bone Property
BV/TV (%/kg)
Tb. N (l/mm*kg)
Tb. Th (mm/kg)
Tb. Sp (mm/kg)
App. Mn. Dn
(mgHA/(cm3*kg))
Mat. Mn. Dn.
(mgHA/(cm3*kg))

Vehicle
1.61 (0.75) “• b
97.0 (21.9)
1.22 (0.08)
8.94 (2.35)
2729 (1029) “• b
28667 (1534)

hPTH 1-84
1.34 (0.83) b
98.7 (20.1)
1.26 (0.18)
9.57 (2.04)
2513 b (1118)

bbPTH 1-84
2.26 (0.72) “
113.8 (24.3)
1.38 (0.17)
8.47 (2.36)
3665 (935) “

ANOVA
p-value
0.038
0.193
0.055
0.558
0.043

29810 (2317)

30552 (1374)

0.077

Standard deviations are shown in parentheses.
Different superscripts indicate significant differences (p < 0.05) between groups.
See text for explanations of abbreviations.
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Cortical Bone Mechanical Properties and Ash Fraction of
the Femur

Cortical Bone Geometrical Properties in the Femur
Bone periosteal area was highest in vehicle treated mice
from the PTF1 1-34 study and lowest in vehicle-treated mice
Ultimate load of the femur was increased by peptide treat from the PTF11-84 study (Table 3). Mice treated with bbPTFl
1-84, but not hPTFl 1-84, had significantly greater values for
ment (+3% to +15% compared to vehicle-treated mice) (FIG. 5 periosteal
area compared to vehicle-treated mice, but mice
29). The increase in bone strength was significantly treated with both PTF1 1-34 peptides had lower values for
(p=0.032) greater in mice treated with bbPTFl 1-84 compared periosteal area compared to vehicle treated mice (Table 3).
to hPTFl 1-84, but was not different (p=0.819) between mice Neither cortical bone area nor endosteal area were different
treatment groups (p>0.136). Cortical bone thickness
treated with bbPTFl 1-34 andhPTFl 1-34. Bone mineral con 10 between
was greater in mice from the PTF11-84 study compared to the
tent (ash fraction) was not different between the treatment PTF11-34 study, but there were no other differences between
treatment groups (Table 3).
groups (p=0.180) (data not shown).
TABLE 3
Cortical bone geometrical properties in the femoral midshaft of PTH-treated mice.
Bone
property
Ps.Ar
(mm2/k 2)
Ct.Ar
(mm2/k 2)
Es.Ar
(mm2/k 2)
Ct.Th
(mm/kg)

Vehicle
(1-34)
60.5 (7.5)"

hPTH
bbPTH
Vehicle
1-34
1-34
(1-84)
55.3 (5.2)b-c 56.0 (3 .6 )b-c 53.7 (3.6)c

hPTH
bbPTH
1-84
1-84
54.6 (A A )b-c 58.3 (5.0)“-*

31.3 (2.9)

30.7 (3.0)

31.7 (3.5)

28.9 (2.9)

29.0 (3.7)

31.7 (3.7)

0.194

29.2 (7.5)

24.7 (3.7)

24.3 (2.0)

24.8 (2.9)

25.6 (3.3)

26.6 (4.6)

0.136

1.97 (0.19)4 2.22 (0.20)4 2.14 (0 .2 6 )b 3.29 (0.40)" 3.41 (0.59)" 3.56 (0.42)"

ANOVA
p-value
0.042

<0.0001

Standard deviations are shown in parentheses.
Different superscripts indicate significant differences (p < 0.05) between groups.
See text for explanations of abbreviations.

Cortical Bone Dynamic Flistomorphometry in the Femur
There were no significant differences in periosteal or
endosteal mineralizing surface or mineral apposition rate
between treatment groups (p>0.236) (Table 4).
TABLE 4
Cortical bone dynamic histomorphometry in the femoral midshaft of PTH-treated mice.
Bone
property

Vehicle
(1-34)

Periosteal 20.9 (13.8)

hPTH
1-34

bbPTH 134

Vehicle
(1-84)

hPTH
1-84

bbPTH
1-84

ANOVA
p-value

24.0 (13.8)

28.9 (13.6)

22.2 (10.6)

20.2 (16.7)

31.3 (22.5)

0.526

39.3 (17.7)

31.2 (25.9)

27.8 (14.3)

32.1 (19.4)

24.5 (17.2)

0.317

0.53 (0.21)

0.64 (0.21)

0.69 (0.34)

0.60 (0.40)

0.62 (0.33)

0.490

0.56 (0.18)

0.63 (0.26)

0.81 (0.25)

0.62 Q.39)

0.59 (0.42)

0.236

MS/BS
Endosteal 20.4 (16.7)
MS/BS
Periosteal 0.44 (0.23)
MAR
Endosteal 0.47 (0.20)
MAR

Standard deviations are shown in parentheses.
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CONCLUSIONS
These Data indicate that bbPTH 1-34 is more anti-apoptotic than hPTH 1-34 and hPTH 1-84 in vitro, however,
bbPTH 1-84 increases bone volume and strength in mice
more than hPTH peptides. This suggests bbPTH has potential
as a new anabolic therapy for osteoporosis.
The hPTH peptides in these studies did not produce an
increase in trabecular bone mass compared to vehicle treat
ment (Tables 1 and 2), likely because of the relatively low
peptide dosage administered to the mice. Short-term in vivo
studies of PTH’s anabolic effects in mice typically use pep
tide dosages >10 nmol/kg to produce a large increase in bone
formation and bone mass over a short period of time. In
previous studies, lower peptide dosages are less osteogenic in
short-term studies; daily injections of 1 nmol/kg hPTH 1-34
for 6 weeks did not affect trabecular thickness (Tb.Th) or
mineral apposition rates (MAR) in the proximal tibia of male
mice, whereas a higher molar dosage of hPTH (-10 nmol/kg)
increased these properties. See Sakai et al. (1999) J Bone
Miner Res 14(10): 1691-9. A dosage of 2.5 nmol/kg was used
in our studies because it is the lowest peptide dosage shown to
increase osteoblast number and decrease osteoblast apoptosis
in trabecular bone secondary spongiosa in mice (see Bellido
et al. (2003) J Biol Chem 278(50): 50259-72), and it is closer
to a clinical dosage (20 pg/day, approximately 0.07 nmol/kg
for a 70 kg patient) compared to PTH dosages used in other
short-term in vivo studies. Although hPTH peptides did not
increase trabecular bone mass at 2.5 nmol/kg, mice treated
with the same dosage of bbPTH 1-84 showed improvement in
trabecular bone properties (Table 2) and cortical bone
strength (FIG. 29) compared to hPTH 1-84. Trabecular thick
ness tended to be elevated in mice treated with bbPTH 1-84
(Table 2). Importantly, trabecular bone volume fraction and
apparent mineral density were only significantly increased
over vehicle treatment by bbPTH 1-84 (Table 2). Most of the
peptide analogs investigated tended to increased femoral ulti
mate load, but the increase over vehicle treatment was only
statistically significant for bbPTH 1-84 (FIG. 29). Taken
together, these findings raise the possibility that bbPTH may
be an effective osteogenic therapy at a lower dose than hPTH.
All PTH peptides used in the current study attenuated
apoptotic signaling induced by serum starvation in vitro (FIG.
19). bbPTH 1-34 reduced apoptotic signaling in pre-osteoblastic cells more than human PTH (FIG. 19). Recently, we
found similar results with preliminary studies in human fetal
osteoblasts (hFOB). Serum starvation for 24 hours increased
cell death in hFOB (confirmed via trypan blue staining), but
pretreatment of hFOB cells with 100 nM PTH 1-34 or 1-84
for 1 hour before starvation reduced percent cell death (per
centage change in cell death compared to vehicle pretreat
ment, hPTH 1-34: -18%, bbPTH 1-34: -25%, hPTH 1-84:
-17%, bbPTH 1-84: -21%; p<0.0001; data not shown). The
enhanced anti-apoptotic effects of bbPTH 1-34 led to the
expectation that bbPTH 1-34 would be the most potent osteo
genic agent in vivo. However, although bbPTH 1-84 was less
anti-apoptotic than bbPTH 1-34 and hPTH 1-34 in vitro (FIG.
19) it caused the greatest increases in cortical and trabecular
bone mass in the in vivo studies (Table 1, Table 2).
The disparity between the in vitro and in vivo studies
cannot be reconciled at present. Reducing osteoblast apopto
sis is a dominant process in hPTH’s anabolic effects on tra
becular bone, but it is possible that other biological mecha
nisms regulate bbPTH’s ability to increase bone mass. For
example, increasing osteoblast differentiation (rather than
preventing osteoblast apoptosis) is the primary means by
which hPTH stimulates periosteal cortical bone formation.
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Consistent with this concept, femoral bone strength was
greatest in mice treated with bbPTH 1-84 (FIG. 29). Bone
volume fraction in the proximal tibia was also greatest in mice
treated with bbPTH 1-84 (Table 1), even though bbPTH 1-84
was less anti-apoptotic than the other peptide analogs tested
in MC3T3 cells. While the 1-34 fragment of hPTH is suffi
cient to replicate the anabolic effects of the full hPTH peptide,
the fact that bbPTH 1-84 demonstrated a superior perfor
mance in vivo compared to both bbPTH 1-34 and both hPTH
peptides suggests that the amino acid changes in bbPTH’s
C-terminal portion may be involved in receptor binding and
receptor activation behavior.
Example 15
In Vivo Effects of Human PTH 1-84 and Bear
PTH 1-84 in Ovariectomized Rats
Thirty female, 2.5-month old Sprague-Dawley rats were
ovariectomized (OVX) at the commercial breeding facility
The OVX animals were randomly assigned into 3 groups of
10 animals per group for further experiments.
Six weeks after the OVX procedure, the rats were injected
subcutaneously for an eight-week period (daily for five days
per week) with vehicle (saline) or 2.5 nmol/kg bear or human
PTH1-84. Animals were euthanized 24 hours after the last
injection. Samples were obtained from the euthanized ani
mals for further analysis.
Femur bending strength and proximal tibia trabecular
architecture were investigated as described in Example 12.
In this experiment, the ultimate load of the femur was
significantly (p=0.013) increased by bbPTHl-84 treatment
compared to vehicle treatment, but not by human PTH1-84
(p=0.463) (FIG. 20). These findings indicate that bbPTHl-84
is more efficacious at reversong OVX-induced bone loss in
rats than human PTH 1-84 is. Normalized ultimate load of the
femur, however, was not significantly (p=0.131) affected by
PTH treatment (FIG. 21). This measure is a more physiologi
cal measure of bone strength than non-normalized load; it is
likely bbPTHl-84 would become significanity greater than
human PTH 1-84 will higher sample sizes to provide greater
statistical power.
The bone volume fraction was increased in PTH treated
groups (FIG. 22). The trabecular number was not affected by
PTH treatment (FIG. 23), although the trabecular thickness
was increased in PTH treated groups (FIG. 24). The trabecu
lar separation did not differ between treated and untreated
groups (FIG. 25). The apparent mineral density increased in
PTH-treated groups (FIG. 26), but the material mineral den
sity was not different between the treated and untreated
groups (FIG. 27). In summary, these data suggest that human
and black bear PTH 1-84 equivalently increase trabecular
bone volume (FIG. 26), but bbPTHl-84 shows greater
increases in cortical bone strength than hPTHl -84 (FIGS. 24
and 25). These findings suggest bbPTHl -84 has the potential
to be an efficacious osteoporosis drug for humans.
Example 16

60

Hibernation Bear Serum Reduces Caspase Activity
In Vitro

65

Serum was collected from 6 black bears every 10 days from
early November till the beginning of May, for a total of 6
active pre-hibernation (November-December), 9 hibernation
(January-March), and 4 active post-hibernation (April-May)
samples from each bear. To determine whether bear serum has
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seasonal effects on osteoblast response to apoptotic stimulus, PBS and 50 uL of luminescent DEVD substrate (Caspase-glo
MC3T3-E1 pre-osteoblasts were seeded in Alpha-Modified 3/7, Promega, Madison, Wis.). Luminescence was quantified
Minimum Essential Media (-MEM) with 10% fetal bovine on a Syneigy HT Multi-Detection Microplate Reader (Bioserum at 10,000 cells per well in a white-walled tissue culture Tek, Winooski Vt.). As shown in FIG. 28, caspase-3/7 activity
plate and allowed to attach overnight. Media was then aspi- 5 of cells cultured in hibernation sera was lower than those
rated and replaced with 2% seasonal bear serum in -MEM for cultured in active sera (p<0.0001). These findings indicate
a 24 hour treatment. Media was again aspirated and replaced that seasonal changes in circulating factors (e.g., hormones)
with serum free -MEM for 6 hours to induce apoptosis. provide an anti-apoptotic effect to osteoblasts during hiber
Media was aspirated a final time and replaced with 50 uL of nation.
TABLE 6
Sequences
SEQ
ID
NO Description

Sequence

1 Polynuc1eo t ide
encoding black
bear PTH1-84
(bbPTHl-84)

TCTGTGAGCG
ATCTGAGCTC
GCTGCAGGAC
ACAGCGCACA
AGGAAGACAA
CGGAGAAGCA
GCTAAATCCC

AGATACAGTT
CATGGAGAGG
GTGCACAACT
GAGATGGTGG
TGTGCTGGTT
GACAAAGCTG
AGTGAGAATT

2 black bear
PTH1-84
(bbPTHl-84)

SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAP
TAHRDGGSQR PQKKEDNVLV ENHQKSLGEA DKADVDVLTK
AKSQ

3 Polynuc1eo t ide
encoding full
length black
bear PTH
(bbPTH)

ATGATGTCTG
TGTTTGCAAT
TGTTAAGAAG
AACCTGGGCA
GGCTGCGGAA
CCTTGGAGCT
AGGCCCCAGA
ATCAAAAAAG
TGTATTAACT

4 full length
black bear
PTH (bbPTH)

MMSAKDMVKV MIVMFAICFL AKSDGKPVKK RSVSEIQFMH
NLGKHLSSME RVEWLRKKLQ DVHNFVALGA PTAHRDGGSQ
RPQKKEDNVL VENHQKSLGE ADKADVDVLT KAKSQ

5 monkey PTH184

SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNFIALGAP
LAPRDAGSQR PRKKEDNILV ESHEKSLGEA DKADVDVLTK
AKSQ

6 human PTH184 (hPTHl-84)

SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNFVALGAP
LAPRDAGSQR PRKKEDNVLV ESHEKSLGEA DKADVNVLTK
AKSQ

7 horse PTH184

SVSEIQLMHN LGKHLNSVER VEWLRKKLQD VHNFIALGAP
IFHRDGGSQR PRKKEDNVLI ESHQXSLGEA DKADVDVLSK
TKSQ

8 dog PTH1-84

SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAP
IAHRDGSSQR PLKKEDNVLV ESYQKSLGEA DKADVDVLTK
AKSQ

9 cat PTH1-84

SVSEIQFMHN LGKHLSSVER VEWLRRKLQD VHNFVALGAP
IAHRDGGSQR PRKKEDNVPA ENHQKSLGEA DKADVDVLIK
AKSQ

10 bovine PTH184

AVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVALGAS
IAYRDGSSQR PRKKEDNVLV ESHQKSLGEA DKADVDVLIK
AKPQ

11 pig PTH1-84

SVSEIQLMHN LGKHLSSLER VEWLRKKLQD VHNFVALGAS
IVHRDGGSQR PRKKEDNVLV ESHQKSLGEA DKAAVDVLIK
AKPQ

12 rat PTH1-84

AVSEIQLMHN LGKHLASVER MQWLRKKLQD VHNFVSLGVQ
MAAREGSYQR PTKKEENVLV DGNSKSLGEG DKADVDVLVK
AKSQ

13 mouse PTH184

AVSEIQLMHN LGKHLASMER MQWLRRKLQD MHNFVSLGVQ
MAARDGSHQK PTKKEENVLV DGNPKSLGEG DKADVDVLVK
SKSQ

CGAAAGACAT
TTGTTTTCTT
AGATCTGTGA
AACATCTGAG
GAAGCTGCAG
CCAACAGCGC
AAAAGGAAGA
TCTCGGAGAA
AAAGCTAAAT

TATGCATAAC
GTGGAATGGC
TTGTTGCCCT
TTCCCAGAGG
GAGAACCATC
ATGTGGATGT
C

GGTTAAAGTA
GCAAAATCGG
GCGAGATACA
CTCCATGGAG
GACGTGCACA
ACAGAGATGG
CAATGTGCTG
GCAGACAAAG
CCCAGTGAGA

CTGGGCAAAC
TGCGGAAGAA
TGGAGCTCCA
CCCCAGAAAA
AAAAAAGTCT
ATTAACTAAA

ATGATTGTCA
ATGGGAAACC
GTTTATGCAT
AGGGTGGAAT
ACTTTGTTGC
TGGTTCCCAG
GTTGAGAACC
CTGATGTGGA
ATTC
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TABLE 6-continued
Secfuences
SEQ
ID
NO Description

Sequence

14 hPTHl-34

SVSEIQLMHN LGKHLNSMER VEWLRKKLQD VHNF

15 bbPTHl-34

SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNF

16 bbPTHl-36

SVSEIQFMHN LGKHLSSMER VEWLRKKLQD VHNFVA

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 16
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH: 261
TYPE: DNA
ORGANISM: Ursus americanus

<400> SEQUENCE: 1
tctgtgagcg agatacagtt tatgcataac ctgggcaaac atctgagctc catggagagg

60

gtggaatggc tgcggaagaa gctgcaggac gtgcacaact ttgttgccct tggagctcca

120

acagcgcaca gagatggtgg ttcccagagg ccccagaaaa aggaagacaa tgtgctggtt

180

gagaaccatc aaaaaagtct cggagaagca gacaaagctg atgtggatgt attaactaaa

240

gctaaatccc agtgagaatt c

261

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH: 84
TYPE: PRT
ORGANISM: Ursus americanus

<400> SEQUENCE: 2
Ser Val Ser Glu H e
1
5

Gin Phe Met His Asn Leu Gly Lys His Leu Ser
10
15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser
35
40
45
Gin Arg Pro Gin Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gin
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH: 354
TYPE: DNA
ORGANISM: Ursus americanus

<400> SEQUENCE: 3
atgatgtctg cgaaagacat ggttaaagta atgattgtca tgtttgcaat ttgttttctt

60

gcaaaatcgg atgggaaacc tgttaagaag agatctgtga gcgagataca gtttatgcat

120

aacctgggca aacatctgag ctccatggag agggtggaat ggctgcggaa gaagctgcag

180

gacgtgcaca actttgttgc ccttggagct ccaacagcgc acagagatgg tggttcccag

240

aggccccaga aaaaggaaga caatgtgctg gttgagaacc atcaaaaaag tctcggagaa

300
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-continued
gcagacaaag ctgatgtgga tgtattaact aaagctaaat cccagtgaga attc

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH: 115
TYPE: PRT
ORGANISM: Ursus americanus

<400> SEQUENCE: 4
Met Met Ser Ala Lys Asp Met Val Lys Val Met lie Val Met Phe Ala
1
5
10
15
He

Cys Phe Leu Ala Lys Ser Asp Gly Lys Pro Val Lys Lys Arg Ser
20
25
30

Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser Ser
35
40
45
Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His Asn
50
55
60
Phe Val Ala Leu Gly Ala Pro Thr Ala His Arg Asp Gly Gly Ser Gin
65
70
75
80
Arg Pro Gin Lys Lys Glu Asp Asn Val Leu Val Glu Asn His Gin Lys
85
90
95
Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala
100
105
110
Lys Ser Gin
115

<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH: 84
TYPE: PRT
ORGANISM: Macaca fascicularis

<400> SEQUENCE: 5
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe lie Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn lie Leu Val Glu Ser His Glu
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH: 84
TYPE: PRT
ORGANISM: Homo sapiens

<400> SEQUENCE: 6
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu
50
55
60

354
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Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gin

<210>
<211>
<212>
<213>
<220>
<221>
<222 >
<223>

SEQ ID NO 7
LENGTH: 84
TYPE: PRT
ORGANISM: Equus caballus
FEATURE:
NAME/KEY: misc_feature
LOCATION: (65).. (65)
OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 7
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Val Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe H e Ala Leu Gly Ala Pro lie Phe His Arg Asp Gly Gly Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu lie Glu Ser His Gin
50
55
60
Xaa Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Ser Lys
65
70
75
80
Thr Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH: 84
TYPE: PRT
ORGANISM: Canis lupus

<400> SEQUENCE: 8
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro lie Ala His Arg Asp Gly Ser Ser
35
40
45
Gin Arg Pro Leu Lys Lys Glu Asp Asn Val Leu Val Glu Ser Tyr Gin
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys
65
70
75
80
Ala Lys Ser Gin

<210>
<211>
<212>
<213 >

SEQ ID NO 9
LENGTH: 84
TYPE: PRT
ORGANISM: Felis catus

<400> SEQUENCE: 9
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Val Glu Arg Val Glu Trp Leu Arg Arg Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Pro lie Ala His Arg Asp Gly Gly Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Pro Ala Glu Asn His Gin
50
55
60

40
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Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu lie Lys
65
70
75
80
Ala Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH: 84
TYPE: PRT
ORGANISM: Bos taurus

<400> SEQUENCE: 10
Ala Val Ser Glu H e
1
5

Gin Phe Met His Asn Leu Gly Lys His Leu Ser
10
15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Ser lie Ala Tyr Arg Asp Gly Ser Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gin
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asp Val Leu lie Lys
65
70
75
80
Ala Lys Pro Gin

<210>
<211>
<212>
<213>

SEQ ID NO 11
LENGTH: 84
TYPE: PRT
ORGANISM: Sus scrofa

<400> SEQUENCE: 11
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala Leu Gly Ala Ser lie Val His Arg Asp Gly Gly Ser
35
40
45
Gin Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Gin
50
55
60
Lys Ser Leu Gly Glu Ala Asp Lys Ala Ala Val Asp Val Leu lie Lys
65
70
75
80
Ala Lys Pro Gin

<210>
<211>
<212>
<213>

SEQ ID NO 12
LENGTH: 84
TYPE: PRT
ORGANISM: Rattus norvegicus

<400> SEQUENCE: 12
Ala Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Ala
1
5
10
15
Ser Val Glu Arg Met Gin Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ser Leu Gly Val Gin Met Ala Ala Arg Glu Gly Ser Tyr
35
40
45
Gin Arg Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Ser
50
55
60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65
70
75
80

42
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Ala Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 13
LENGTH: 84
TYPE: PRT
ORGANISM: Mus musculus

<400> SEQUENCE: 13
Ala Val Ser Glu H e
1
5

Gin Leu Met His Asn Leu Gly Lys His Leu Ala
10
15

Ser Met Glu Arg Met Gin Trp Leu Arg Arg Lys Leu Gin Asp Met His
20
25
30
Asn Phe Val Ser Leu Gly Val Gin Met Ala Ala Arg Asp Gly Ser His
35
40
45
Gin Lys Pro Thr Lys Lys Glu Glu Asn Val Leu Val Asp Gly Asn Pro
50
55
60
Lys Ser Leu Gly Glu Gly Asp Lys Ala Asp Val Asp Val Leu Val Lys
65
70
75
80
Ser Lys Ser Gin

<210>
<211>
<212>
<213>

SEQ ID NO 14
LENGTH: 34
TYPE: PRT
ORGANISM: Homo sapiens

<400> SEQUENCE: 14
Ser Val Ser Glu lie Gin Leu Met His Asn Leu Gly Lys His Leu Asn
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe

<210>
<211>
<212>
<213>

SEQ ID NO 15
LENGTH: 34
TYPE: PRT
ORGANISM: Ursus americanus

<400> SEQUENCE: 15
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe

<210>
<211>
<212>
<213>

SEQ ID NO 16
LENGTH: 36
TYPE: PRT
ORGANISM: Ursus americanus

<400> SEQUENCE: 16
Ser Val Ser Glu lie Gin Phe Met His Asn Leu Gly Lys His Leu Ser
1
5
10
15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gin Asp Val His
20
25
30
Asn Phe Val Ala
35

45
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What is claimed is:
1. A method of increasing cAMP levels in a bone-forming
cell comprising administering 0.10 pg/kg per day to 40 pg/kg
per day of a polypeptide comprising SEQ ID NO: 2 to a
human subject in need thereof.
2. A method of reducing apoptosis in a bone-forming cell
comprising administering 0.10 pg/kg per day to 40 pg/kg per
day of a polypeptide comprising SEQ ID NO: 2 to a human
subject in need thereof.
3. A method of decreasing the ratio of expression levels of
Bax protein to Bcl-2 protein in a bone-forming cell compris
ing administering 0.10 pg/kg per day to 40 pg/kg per day of a
polypeptide comprising SEQ ID NO: 2 to a human subject in
need thereof.
4. A method of increasing the expression level of one or
more of a bone matrix protein, a transcriptional activator, or a
transcriptional regulator in a bone-forming cell comprising
administering 0.10 pg/kg per day to 40 pg/kg per day of a
polypeptide comprising SEQ ID NO: 2 to a human subject in
need thereof.
5. A method of enhancing bone mineral density, increasing
bone mass, decreasing bone loss, or reducing the incidence of

5
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bone fractures, or any combination thereof, in a human sub
ject in need thereof, comprising contacting a bone-forming
cell in the subject with 0.10 pg/kg per day to 40 pg/kg per day
of a polypeptide comprising SEQ ID NO: 2.
6. The method of claim 5, wherein the subject is a post
menopausal female human afflicted with osteoporosis.
7. The method of claim 5 further comprising administering
vitamin D and calcium to the subject.
8. A method of increasing bone volume, increasing bone
mineral apparent density, increasing number of trabecular
struts, increasing thickness of trabecular struts, increasing
trabecular bone mineralization, increasing cortical bone vol
ume, decreasing cortical porosity, or decreasing serum cal
cium, or any combination thereof, in a human subject in need
thereof, comprising contacting a bone-forming cell in the
subject with 0.10 pg/kg per day to 40 pg/kg per day of a
polypeptide comprising SEQ ID NO: 2.
9. The method of claim 8, wherein the subject is a post
menopausal female human afflicted with osteoporosis.
10. The method of claim 8, further comprising administer
ing vitamin D and calcium to the subject.

